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History
In 1883, Kobylinkski described the first patient with clinical features compatible with 
Noonan syndrome (1). In his report ‘Ueber eine flughautahnliche Ausbreiting am Halse’ 
he reported a 20-year old male with marked webbing of the neck, which was a defining 
characteristic in early reports. In 1930, Ullrich described patients with webbed neck 
and short stature (2). In retrospect they represented patients with both Turner 
syndrome and Noonan syndrome. Henry Turner presented older patients with sexual 
infantilism, short stature, webbed neck and cubitus valgus (3). Turner syndrome was 
later recognized as a sex-linked disease. Ullrich recognized both females and males 
with a similar phenotype, which he named ‘Bonnevie-Ullrich’ (after Bonnevie’s work on 
mice) (4). As a result of these publications, the term ‘Ullrich-Turner syndrome’ was born. 
Furthermore the terms ‘male Turner syndrome’ or ‘Turner syndrome with normal 
chromosomes’ were introduced (5,6,7,8). 
In 1963, Jacqueline Noonan (pediatric cardiologist) performed a clinical study on 
associated non-cardiac anomalies in children with congenital heart disease (9). In nine 
patients characteristic facial features, including hypertelorism, low-set posteriorly rotated 
ears, downslanting palpebral fissures and ptosis, were identified. Furthermore pulmonary 
stenosis, short stature, chest deformity and undescended testes in males were described. 
Chromosome studies were normal. Five years later she supplemented an additional ten 
patients to the earlier described group of nine. The group was named ‘Hypertelorism 
with Turner phenotype’ (10). As Jacqueline Noonan was the first to describe this group, 
John Opitz suggested the eponym Noonan syndrome and in 1968 this eponym was used 
for the first time (11,12). 
Clinical characteristics
Noonan syndrome has a variable phenotype and it is diagnosed clinically by a 
combination of features. Facial features play an important role in diagnosing Noonan 
syndrome. Other characteristics include congenital heart defect, short stature, chest 
wall deformity, cryptorchidism, skeletal abnormality, lymphatic dysplasia and 
developmental delay (13-16). Different mutations are described but Noonan 
syndrome still is a clinical diagnosis. Van der Burgt developed a scoring system, which 
was updated in 2007 (16). These criteria help in the diagnosing process but are also 
of value in the research domain. The scoring system is embedded in the clinical 
guideline for Noonan syndrome that was published in 2010 (14, 17). 
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Prenatal features
Noonan syndrome and other RASopathies should be considered as a possible diagnosis 
in pregnancies with a normal karyotype and different prenatal ultrasound findings. 
These ultrasound findings include polyhydramnios, macrosomia, lymphatic dysplasia 
(including increased nuchal translucency and cystic hygroma), cardiac anomalies and 
renal anomalies (18). Recognition of common perinatal findings can facilitate an early 
neonatal diagnosis. 
Growth
Approximately 50-70% of the Noonan syndrome patients have short stature but normal 
height can also be reached (14,19,20). Noonan syndrome-specific growth charts have 
been described in literature (21-24). Birth length and weight are usually normal (13). 
In the first year of life growth failure often starts to occur and is considered as an 
intrinsic growth failure (25). From approximately two to four years until puberty height 
follows the third percentile (or -2 SDS). The onset of puberty is often delayed and the 
growth spurt is often delayed and reduced. The bone age has a mean delay of 2 years 
(14,21). The mean final height described in females is 148.4-153.3 centimeters and in 
males is 157.4-169.8 centimeters. As bone maturity can be delayed, prolonged growth 
into the twenties is found (21-23,26,27). Various mechanisms for the short stature are 
reported. In Noonan syndrome the growth failure is mainly of postnatal character. The 
intrinsic primary failure is suggested to be due to insufficient growth hormone 
secretion, growth hormone resistance and dysregulation of the RAS/MAPK signaling 
pathway (28-30). Growth hormone stimulation tests are reported as normal and height 
gain in Noonan syndrome patients treated with growth hormone is presented in 
literature (31)
Table 1. Noonan syndrome scoring system
Major Minor
Facial typical face dysmorphology suggestive face dysmorphology
Cardiac pulmonary valve stenosis, 
HOCM and/or ECG typical for NS
other defect
Height <3rd centile <10th centile
Chest wall pectus carinatum/ excavatum broad thorax
Family history first-degree relative with definite NS first-degree relative with suggestive NS
Other mental retardation, cryptorchidism and 
lymphatic dysplasia
either mental retardation, cryptorchidism or 
lymphatic dysplasia
Definite NS is diagnosed by: (1) typical face dysmorphology +1 other major sign or 2 minor signs, or (2) suggestive face 
dysmorphology + 2 other major signs or 3 minor signs. HOCM = Hypertrophic obstructive cardiomyopathy. Table adapted 
from van der Burgt (16).
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Craniofacial features
Characteristic facial dysmorphisms play an important role in diagnosing Noonan 
syndrome and have a dominant function in the scoring system. Changes in phenotype 
are described when the patients get older (32). The facial appearance is most 
characteristic during infancy with a large head and forehead, wide-spaced eyes, 
downslanting palpebral fissures, epicanthic folds, low-set posteriorly rotated ears, high 
arched palate, micrognathia and short neck with excess nuchal skin and low posterior 
hairline. With the age the shape of the face becomes more triangular and during 
childhood the face can lack expression and looks myopathic with prominent eyes and 
ptosis. By adolescence, the neck is less short, eyes are less prominent, and the face is 
in the shape of an inverted triangle. Adults can have unremarkable faces but other 
adult Noonan syndrome patients can present with typical features including ptosis, 
hypertelorism, low-set ears and webbed neck (14,16,31-33). 
Cardiovascular features
Cardiovascular abnormalities in Noonan syndrome occur in up to more than 80% 
(31,34, 35). The most common congenital heart anomaly is the pulmonary valve 
stenosis and the valve is often dysplastic. Furthermore, a variety of cardiac abnormalities 
are described including the atrial septal defect, ventricular septal defect and 
hypertrophic cardiomyopathy (13,14,26,36). Less frequent heart defects include 
coarctatio aortae, tetralogy of Fallot, atrioventricular canal, aortic stenosis, patent 
ductus arteriosus, coronary artery anomaly and mitral valve anomaly (14,34,36,37). 
The electrocardiogram (ECG) in Noonan syndrome is characterized by left axis deviation, 
wide QRS complexes and small R waves in the left precordial lead (14,34,35,37,38). 
Psychological health and cognitive issues
There is a wide range in the level of intelligence. The average level of the mean full-scale 
intelligence quotient (IQ) is 85 and this is 10 points less than unaffected family members. 
Intellectual disability and learning disabilities are usually mild and described in 15-35% 
of the patients (39,40). Delay in language development and articulation abnormalities 
are found frequently (39-41). Behavioral issues described in Noonan syndrome are 
attention deficits, social problems, irritability, anxiety, fidgety, poor coordination and 
eating problems. Most Noonan patients are raised by parental support alone without 
other interventions, finish high school and have paying jobs (26,41,42,43). Cognitive 
problems and difficulties in processing affective information are found in Noonan 
syndrome including alexithymia and deficiencies in social and emotional recognition 
(44,45). Limited literature is available on psychological and psychiatric problems in 
Noonan syndrome. In one study with NS adults, depression is described in 49% (46). 
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Musculoskeletal abnormalities, neurologic features, and motor development
Chest wall anomalies have a prominent role in diagnosing Noonan syndrome. In the 
clinical scoring system a pectus excavatum or pectus carinatum are major signs and a 
broad thorax is a minor sign (16). Pectus carinatum is superiorly and pectus excavatum 
is inferiorly seen in Noonan syndrome, together described in up to 95% of the patients 
(14). Spinal and vertebral deformities are seen including scoliosis. Other orthopedic 
features include talipes equinovarus, radio-ulnar synostosis, joint contractures, and 
hyperextensible joints (14-16,47). 
Difficulties and delay in motor performance and hypotonia are frequently reported in 
Noonan syndrome. The average age for sitting unsupported is ten months and walking 
21 months (14). Developmental coordination disorders including clumsiness are 
described in up to 50% (48). Impaired manual dexterity is also described and is 
correlated with nonverbal and verbal intellectual functions (49).  Chronic pain (joints, 
extremities, muscles) is described in more than 50% of the Noonan syndrome patients 
(46,50). Neurologic problems and brain abnormalities are described seldom. Arnold-
Chiari malformation and hydrocephaly are mentioned in literature. Other neurologic 
features are epilepsy, peripheral neuropathy and craniosynostosis (14,15,51).
Genitourinary problems
In up to 80% of the boys cryptorchidism, both unilateral and bilateral, is described and 
surgical orchiopexy is required (14). Male gonadal dysfunction is reported and 
suggested to be due to Sertoli cell dysfunction (52). Puberty in male can be delayed or 
inadequate and is associated with deficient spermatogenesis and puberty in female 
can be delayed but a normal fertility is expected (53).
Lymphatic issues
Lymphatic dysplasia is a feature in the clinical scoring system. Lymphatic dysplasia, 
hypoplasia or aplasia is described in approximately 20% of the Noonan syndrome 
patients and it can occur in all ages (54). Peripheral lymphedema is the most common 
manifestation. Different lymphatic issues are described in a few Noonan syndrome 
patients, including hydrops, chylous pleural effusion, pulmonary and intestinal 
lymphangiectasis and anomalous lymphatic vessels (31,33). 
Hematology and oncology
Bleeding disorders are reported in 30-65% of the individuals with Noonan syndrome 
(14,55). Most have a positive bleeding history with mild symptoms of epistaxis, excessive 
bruising or bleeding with surgery. Different etiologies are described including platelet 
function defect, thrombocytopenia, Von Willebrand disease, and coagulation factor 
deficiency (56). Special care is required for surgery in Noonan syndrome patients.
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Acute leukaemia and myeloproliferative disorders are described in Noonan syndrome 
and the incidence is slightly higher than in the general population.  The presenting 
types during childhood include acute lymphoblastic leukaemia (ALL), juvenile 
myelomonocytic leukaemia (JMML), lymphoma, neuroblastoma, and rhabdomyo-
sarcoma. An earlier onset and milder presentation of JMML in Noonan syndrome is 
described (57,58). 
Ocular abnormalities
Ocular anomalies are seen frequently in Noonan syndrome. Face dysmorphology 
is part of the clinical scoring system and include external ocular abnormalities. Most 
frequent external ocular anomalies include hypertelorism, ptosis, epicanthic folds, 
and downslanting palpebral fissures. Other ocular manifestations are found during 
ophthalmologic examinations. The first cohort of ocular manifestations in Noonan 
syndrome is described in 1992 with ophthalmologic examinations in 58 patients 
(59). Their examination revealed strabismus, refractive errors, amblyopia, and 
nystagmus. Anterior segment anomalies consisted of prominent corneal nerves 
and cataracts. Posterior segment anomalies included optic disc hypoplasia and 
myelinated nerves. Few other small cohort studies have been performed afterwards 
(60,61). Studies on visual-motor integration in Noonan syndrome show different 
results varying from delayed coordination to average visual-motor abilities in 
Noonan syndrome children (39,62).   
Hearing impairment
Hearing impairment in Noonan syndrome is mentioned for the first time in 1976 (63). 
In a Noonan syndrome cohort of 146 patients, hearing impairment is described in 
40% (14). Another cohort studied 40 ears and found a sensorineural hearing 
impairment in 50% of the ears (64). The sensorineural impairment is in approximately 
10% found in the low frequency range and 25% in the high frequency range (64). 
Conducted hearing impairment is mostly secondary to recurrent otitis media. Inner 
ear structural abnormalities, including temporal bone abnormalities, have occasionally 
been reported (65).
Other features
Feeding difficulties and failure to thrive during infancy are described in 76% of the 
Noonan patients (14). Described problems are poor suckling, refusal to eat and drink, 
recurrent vomiting, gastro-esophageal reflux and constipation. Feeding problems 
appear to be the result of delayed gastro-intestinal motor development (66). 
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Skin features seen in Noonan syndrome are abnormalities in pigmentation (pigmented 
naevi, café-au-lait spots, lentigines, and keratosis pilaris).  Approximately one third of 
patients have thick, curly hair, and 10% have thin, sparse hair (14).
Etiology and genetics
Noonan syndrome is a genetically heterogeneous autosomal dominant disorder and 
the incidence is reported to be between 1 in 1000 and 1 in 2500 live births (13,14). 
Noonan syndrome is part of the RASopathies and the most common syndrome in the 
RASopathy group. The RASopathies are a clinically defined group of syndromes caused 
by germline mutations in genes that encode components or regulators of the Ras/
mitogen-activated protein kinase (MAPK) pathway (67). The Ras/MAPK pathway (Figure 
1) is one of the best-studied signal transduction pathways and it influences essential 
developmental processes. Ras proteins are small guanosine nucleotide-bound GTPases 
and they are activated by extracellular growth factors binding to receptors (including 
receptor tyrosine kinases (RTK’s), cytokine receptors and extracellular matrix receptors). 
Ras proteins switch between an active GTP-bound (guanosine triphosphate) form and 
an inactive GDP-bound (guanine diphosphate) form. Binding of growth factors and RTK’s 
Figure 1. Ras/MAPK pathway
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   15 24-09-18   08:45
CHAPTER 1
16    
causes RTK autophosphorylation and activates an interaction with the adaptor protein 
growth factor receptor-bound protein 2 (GRB2). GRB2 is bound to son of sevenless 
(SOS). SOS proteins are guanine nucleotide exchange factors (GEF) that exchange the 
rate of GDP for GTP. This increases the level of active GTP-bound Ras (67,68).
The first gene discovered to be responsible for NS was PTPN11 on chromosome 
12q24.1. PTPN11 encodes the nonreceptor-type tyrosine phosphatase SHP-2, which 
implicates several signal transduction pathways and therefore the PTPN11 gene 
influences various developmental processes (69). PTPN11 mutations are seen in 
approximately 50% of the patients with Noonan syndrome. SHP-2 is required for the 
function of the RAS-MAPK pathway. It plays an essential role in the response to growth 
factors, cell adhesion molecules, cytokines and hormones (69,70). After the PTPN11 
mutation was discovered, other mutations are found in the coding genes of the proteins 
that are associated with the function of the RAS-MAPK pathway. KRAS mutations were 
discovered in 2006 and SOS1 mutations were described in 2007 for the first time (71,72). 
The Son of Sevenless homolog 1 (SOS1) gene encodes a guanine nucleotide exchange 
factor (GEF) for RAS proteins. In 70-80% of the Noonan syndrome patients a mutation 
can be found nowadays. Other mutations of the known Noonan syndrome genes 
include: RAF1, RIT1, NRAS, BRAF, MAP2K1, SOS2, A2ML1, RASA2, LZTR1, and RRAS (68).
Other RASopathies with mutations in the Ras/MAPK pathway are studied. Due to the 
same pathway dysregulation, they have numerous overlapping phenotypic features. 
This can make the clinical diagnoses more challenging and genotypes might be 
necessary for the correct diagnoses. Neurofibromatosis type 1 (NF1) was the first 
identified syndrome. Other syndromes in the Ras/MAPK pathway include Noonan 
syndrome with multiple lentigines, Noonan syndrome with loose anagen hair, Costello 
syndrome, Cardio-facio-cutaneous syndrome (CFC), and Legius syndrome (67,68).
The group of RASopathies with developmental disorders including Noonan syndrome 
are caused by germline mutations. The Ras pathway is frequently somatically altered, 
with somatic mutations, in a broad spectrum of neoplasms. The Ras/MAPK pathway 
is studied frequently in neoplasms and is an attractive target for small-molecule 
inhibition to treat varies malignancies. It is suggested that in approximately one third 
of all human cancers, the Ras/MAPK pathway is deregulated by a somatic mutation. 
Recent research shows that children with Noonan syndrome have an eight-fold greater 
risk of developing a childhood cancer compared to children without Noonan syndrome. 
Correlation between specific types of malignancies and genotypes in Noonan syndrome 
is not available and therefore cancer surveillance in Noonan syndrome not 
recommended (58,67).
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Thesis outline
The aim of this thesis is to study different clinical aspects of Noonan syndrome. 
Although the diagnosis of Noonan syndrome can be confirmed with genetic analysis 
in 70-80% of the cases, it remains predominantly a clinical diagnosis. However, the 
great variety of features and phenotypes can make it difficult to diagnose Noonan 
syndrome. Not all features described in Noonan syndrome are included in the scoring 
systems. Additionally, there are different phenotypes described within the same family 
and a changing phenotype in the older patient is mentioned.
In Chapter 2 we focus on the variable phenotypic expressions within a single large 
Noonan syndrome family. In this family a new pathogenic SOS1 mutation was found. 
Clinical data were collected in three different generations. This was the first time that 
phenotypic findings within a single large Noonan syndrome family due to SOS1 mutation 
were published.
Furthermore, studies were focused on the ocular features in Noonan syndrome. Ocular 
features are less frequently described, but they occur very common. The external 
ocular abnormalities, including hypertelorism, ptosis, and epicanthic folds, are part of 
the facial characteristics. Facial features are used in the clinical scoring system, facial 
characteristics are scored as typical of suggestive for Noonan syndrome. Other ocular 
abnormalities described in literature include refractive errors, strabismus, amblyopia 
and abnormalities in the anterior and posterior segment of the eye. In Chapter 3 we 
describe a prospective clinical and genetic study in 25 Noonan syndrome patients on 
ocular abnormalities. All patients underwent extensive ocular examinations and 
genotypes were correlated with phenotypes. Ocular abnormalities were classified in 
‘vision and refraction’, ‘external ocular features’, ‘strabismus and ocular motility’, 
‘anterior segment’, ‘posterior segment’, and ‘intraocular pressure’. In Chapter 4 we 
describe a large retrospective cohort of ocular features. In total 103 patients were 
included, which is the largest cohort of ocular features in Noonan syndrome. The 
primary outcome measures were vision and refraction. For the secondary outcome 
measures all ocular abnormalities were included and we looked at delay between 
diagnosis and the initial ocular examinations. The aim of the study was to show the 
frequency of ocular manifestations and importance of early ocular examinations in 
Noonan syndrome patients.
In Chapter 5 external ear anomalies and hearing impairment in Noonan syndrome 
were studied. In this cohort 97 patients were included and both data on facial features 
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of the ears and hearing impairment were collected and this was correlated to the 
genotypes. The aim of the study was to show the role of hearing impairment in Noonan 
syndrome. We hypothesized that hearing impairment is an important characteristic in 
Noonan syndrome although it has never been described extensively in literature. In 
Chapter 6 we described four Noonan syndrome patients and one patient with Noonan 
syndrome with multiple lentigines, who were all diagnosed with severe to profound 
hearing loss. We studied the results of cochlear implantation in this case series. Hearing 
impairment influences the development of children. These hearing impairment studies 
will answer the questions about advise for audiological examination in Noonan 
syndrome patients and treatment options for those patients with severe hearing loss.
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Abstract
Noonan syndrome (NS) is an autosomal dominant multisystem condition with a variable 
phenotype. The most characteristic features are short stature, congenital heart defects 
and recognizable facial features. Mutations in SOS1 are found in 10-20% of patients 
with NS. Different genotype-phenotype studies mention correlations between SOS1 
mutations and some features, such as ectodermal abnormalities and specific facial 
features. We present a large Noonan syndrome family with a novel pathogenic 
mutation; SOS1 c.3134C>G, p.Pro1045Arg. Ten family members with NS are included 
with genetically confirmed mutation and clinical evaluation. The phenotype shows a 
broad spectrum from only few suggestive features for NS in the older generation to 
typical features in the youngest generation. We report on a novel pathogenic mutation 
in the SOS1 gene and a large clinical spectrum in a NS family with ten genetically 
confirmed affected individuals. 
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Introduction
Noonan syndrome (NS) is an autosomal dominant condition characterized by facial 
features, congenital heart defects, short stature, ocular manifestations, skeletal 
abnormalities, lymphoedema and learning problems (1,2). The first NS gene, PTPN11, 
has been elucidated in 2001. Gain-of-function mutations in PTPN11 are responsible for 
approximately 50% of all cases with NS (3).  Since 2001, other NS-genes have been 
identified. Germline mutations in these genes, leading to dysregulation of the RAS-
MAPK pathway, give NS and NS-like conditions. The genes now known are: SOS1, BRAF, 
RAF1, SHOC2, KRAS, NRAS, MAP2K1, MAP2K2, RIT1, CBL, SOS2, PPP1CB, MRAS and LZTR1 
(4-13). The second most common gene involved in NS is SOS1, described in 10-20% of 
NS cases (14). The Son of Sevenless homolog 1 (SOS1) gene encodes a guanine 
nucleotide exchange factor (GEF) for RAS proteins. The product of this gene may 
regulate RAS proteins by facilitating the change between inactive (GDP-bound) and 
active (GTP-bound) states (15). Frequent clinical manifestations in NS patients with 
SOS1 mutations are ectodermal abnormalities (including sparse eyebrows, dry skin, 
keratosis pilaris), cardiac abnormalities and facial features (16). Cognitive impairment 
and reduced growth due to SOS1 mutations are described less frequently compared 
to the total NS population (17). 
Different studies report on genotype-phenotype correlations for patients with NS due 
to a SOS1 mutation (18,19). Noonan syndrome due to pathogenic SOS1 mutations is 
described as a recognizable distinctive form of Noonan syndrome with ectodermal 
abnormalities but normal growth and development (20). On the other hand the 
difficulty of predicting a genotype based on characteristic clinical features in NS is 
frequently reported (21). One small NS family is described with different clinical 
characteristics between three family members with the same familial SOS1 mutation 
(22).  Furthermore, the photographs of 5 generations in a SOS1 family are shown but 
no further information about the mutation and the characteristics is presented (23).
In this observational study we describe in detail the variable clinical features of ten 
genetically affected family members due to a new SOS1 mutation. To the best of our 
knowledge, this is the first report of a large NS family due to a SOS1 mutation describing 
the phenotype extensively.
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Materials and Methods
For this observational study, we included family members of a large NS family, known 
in the Radboud University Hospital in the Netherlands. After informed consent was 
obtained, the family members were asked for prospective clinical evaluation of NS 
characteristics, photographs and genetic analyses. In total 21 family members 
participated in the clinical evaluation and in 14 family members a genetic analysis was 
performed. In one patient, the proband, all described NS and NS-like genes were 
analyzed and solely a SOS1 mutation was found. 
In all 21 family members the clinical characteristics were scored and photographs were 
taken. The results were reviewed by two of the researchers including an experienced 
clinical geneticist. The characteristics were compared to the NS scoring system, as 
described by van der Burgt (2).
Genetic analysis
In total seventeen genes involved in RASopathies (including NS) were analyzed in the 
index person either by using NGS gene panel or Sanger sequencing (Ion AmpliSeq kit 
2.0, Thermo Fisher Scientific). The sequenced genes are: A2ML1, BRAF, CBL, HRAS, KRAS, 
LZTR1, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, RRAS, SOS1, SOS2, SHOC2 and SPRED1. 
In other family members only exon 20 of the SOS1 gene (NM_005633.3) containing the 
variant of interest was sequenced. 
Results
Clinical results 
Three generations of this family with ages ranging from 8 to 73 years old were included. 
Clinical examination revealed three individuals with the clinical diagnosis of definitive 
NS based on the van der Burgt criteria (2) among the family members with genetic 
analyses. In these three individuals, number III-7, IV-8 and IV-10 in Table 1, two had 
typical facial features including ptosis and one had a suggestive face. In all three a 
pectus excavatum was present. Based on the genetic analysis they all had a first-degree 
relative with NS. No cardiac abnormalities, short stature, cryptorchidism or lymphatic 
dysplasia were found in these individuals. Individual number IV-8 had a mild intellectual 
disability with a verbal intelligence quotient of 91 and a performance intelligence 
quotient of 76. The other seven affected family members had different NS 
characteristics, with milder phenotypes. No congenital heart diseases or short stature 
(below -2 standard deviation) were seen in the affected family members. In three NS 
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patients, sparse eyebrows were noticed without other ectodermal abnormalities. In 
five of these seven individuals both unilateral and bilateral ptosis was present. Ptosis 
was the most frequent facial characteristic within the family. Hypertelorism was present 
in three downslanting palpebral fissures in five, epicanthic folds in one and external 
ear abnormalities (low set, protruding or rotated ears) in six NS patients. In generation 
II, no NS facial features were present. In total, four NS patients had pectus excavatum. 
Table 1. Clinical characteristics family members with SOS1 mutation
Clinical characteristics II-
1
II-
4
II-
7
III
-4
III
-6
III
-7
III
-1
1
IV
-7
IV
-8
IV
-1
0
SOS1 c.3134C>G, p.Pro1045Arg + + + + + + + + + +
Age (years) 69 67 73 42 45 42 47 16 13 10
Gender M F F F F M F M F M
Facial characteristics
• Hypertelorism
• Ptosis
• Up- / downslanting palpebral fissures
• Epicanthic folds
• Ear (low set, rotated, protruding)
• Sparse hair – eyebrows
-
+
+
-
-
-
-
+
-
-
-
+
-
+
-
-
-
-
-
+
-
-
+
-
-
-
-
-
-
+
-
-
+
-
+
+
-
+
+
-
+
-
+
-
-
-
+
-
+
+
+
-
+
-
+
+
+
+
+
-
Amblyopia + - - - - + - - - +
Neck (webbed, short) or low hairline - + - - - - - - + -
Visual impairment (glasses/ lenses) - + + - + + - - + +
Sensorineural hearing impairment - - + - - - - - - -
Pectus deformities - - - - - + - + + +
Cryptorchidism - NA NA NA NA - NA + NA -
Short stature (below -2 SD) - - - - - - - - - -
Skin (keratosis, lentigines, café au lait) - - - - - - - - - -
Congenital heart disease - - - - - - - - - -
Feeding difficulties - - - - - - - - + +
Pain in extremities - - + - + + - - + +
Coagulation difficulties (prolonged bleeding or 
easy hematomas)
- - - - + - - + - -
Mental developmental delay/ intellectual 
disabilities
- - - - - - - - + -
Motor developmental delay - - + - - + + + + +
Social problems - - - - - - - - +/- -
Behavior/ psychological problems +/- - - - - - - + + -
M = male, F = female, NA = Not applicable, SD = standard deviation
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Three of these were in the youngest generation. The results of the clinical examination 
are shown in table 1. 
Further extensive clinical evaluation was done in seven family members in whom no 
genetic analysis was performed. One of these individuals (IV-5) was scored as having 
NS based on the clinical criteria (2). Two family members had suggestive facial features 
(individual IV-3 and IV-4) with hypertelorism, ptosis and epicanthic folds and individual 
IV-5 had epicanthic folds, low set ears, pectus deformity and a developmental delay. 
Individual IV-3 had psychological problems. Amblyopia was present in individual IV-4. 
In individuals III-2 and III-9 only ptosis was found without any other NS characteristics. 
The total family is presented in figure 1. Furthermore, in four family members genetic 
analysis excluded the familiar SOS1 mutation. These four individuals (II-5, IV-6, IV-9, 
IV-11) had no NS characteristics following the van der Burgt criteria, except the first-
degree relative with NS for individuals IV-6, IV-9 and IV-11.
The facial photographs, both frontal and lateral, of individual IV-8, her father (III-7) 
and her grandmother (II-4) are shown in figure 2. Individual IV-8 had low and 
protruding ears, hypertelorism, ptosis and downslanting palpebral fissures. Her 
father had protruding ears and downslanting palpebral fissures. Her grandmother 
has ptosis (with surgical correction). As shown in table 1, apart from ptosis, only 
short neck and sparse eyebrows were present in this individual (II-4). In contrast, in 
Figure 1. Family tree
Black figuration = clinical NS, pos = SOS1 c.3134C>G, p.Pro1045Arg mutation, neg = genetic testing showed no SOS1 
mutation, NT = no genetic testing, black arrow = proband
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the proband (individual IV-8) variable NS characteristics were present including 
typical facial features, low hairline, pectus excavatum and mild intellectual disability. 
Pain and fatigue in extremities were present in both father and daughter (III-7 and 
IV-8).
Figure 2. photographs of proband, father and grandmother
(individuals II-4, III-7 and IV-8)
II-4
III-7
IV-8
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Mutation analysis
Sequencing of the SOS1 gene revealed a heterozygous transversion from cytosine to 
guanine at nucleotide position c.3134C>G leading to a missense mutation p.Pro1045Arg. 
This mutation has not been reported before in literature or in the ExAC database (24). 
However, the index person and one family member carrying this mutation are included 
in an earlier study reporting NS and hearing impairment (25). The amino acid change 
affects an evolutionarily moderately conserved Proline changing it to an Arginine at 
position 1045. The detected p.Pro1045Arg change was detected heterozygously in all 
10 tested and clinically affected family members with permission for genetic testing. 
No pathogenic mutations or variants of uncertain significance are detected in the other 
sixteen tested NS / RASopathy genes in the index case. 
Discussion
In this study we describe a new SOS1 mutation, segregated in a large NS family with 
10 genetically confirmed affected individuals. In the proband (individual IV-8) with 
clinically definitive NS, all NS genes are tested and solely this SOS1 mutation is found. 
There is a broad phenotypic range from almost no NS characteristics to typical 
phenotypic presentation of NS. These findings and the absence in control individuals 
support the pathogenetic role of the SOS1, c.3134C>G, p.Pro1045Arg mutation. 
Genotype-phenotype studies show large inter- and intra-familial variability in clinical 
features of NS due to the different mutations in the different NS genes (21,26). 
From ten family members with the SOS1 mutation, three have suggestive facial 
characteristics for NS (all of them in generation III) and two have a typical NS face (both 
in generation IV). A change in facial phenotype with age is described often in NS. These 
changes may be due to genetic heterogeneity, but can also be caused by changing facial 
characteristics with age (27). 
The facial photographs of 21 individuals with SOS1 mutations from infancy to adulthood 
are described in literature (21).  They describe a high prevalence of coarseness of facial 
features and ptosis. At adult age, characteristic appearance of NS may be present but 
affected individuals can also have unremarkable faces (21).  We have not performed 
a photograph study from infancy to childhood, but we find similar characteristics: 
sparse hair and eyebrows in three and ptosis in seven affected family members at 
adult age. 
In previous research is has been suggested that co-occurring mutations in NS can lead 
to different phenotypes (28,29).  In one patient both a mutation in SHOC2 (c.4A>G, p.
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Ser2Gly) and in PTPN11 (1226G>C, p.Gly409Ala) was found with symptoms associated 
with SHOC2 mutations including ectodermal anomalies. They suggest that the PTPN11 
mutation might have acted as a modifier, with a less typical phenotype than other NS 
patients with the SHOC2 mutation (29). Another patient is described with mutations in 
PTPN11 (c.1121A>G, p.N308S) and SOS1 (c.1654A>G, p.R552G)  with typical NS features 
(28). They conclude that the co-occurring mutations did not have an additive effect and 
does not lead to a more severe phenotype (28). To exclude co-occurring mutations in 
this family as an explanation for the phenotypic differences, we tested all NS spectrum 
genes in the proband and we confirmed solely the SOS1 mutation.
Another hypothesis to explain the large intra-familial variability is described by Moncini 
(22). They studied three family members with SOS1 mutation, c.755T>C, p.I252T and 
phenotypical variation. They conducted research on allelic expressions and found 
different allelic expressions of SOS1 in healthy individuals. They hypothesize that 
epigenetic mechanisms might be responsible for the variable clinical expression of 
SOS1 pathogenic alleles. They stated that further studies on epigenetic mechanisms 
must be performed, to gain more insight in their role in the different allelic expressions 
in NS (22). Different allelic expression is also studied in general, in the human genome 
(30). It is suggested that non-coding regions, located in introns and far away from the 
annotated genes, can be involved in the aetiology of diseases. Further investigation 
into these regulatory mechanisms in NS patients would be of interest for a better 
understanding of differences in phenotypic expression. 
In this study we describe the different phenotypic expressions in a large NS family due 
to a new SOS1 mutation. Variety in clinical expressions plays an important role in 
adequately diagnosing NS patients. Phenotype differs between individuals and between 
the different generations. Further research is required to understand the detailed 
pathophysiology. 
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Abstract
Objective
To determine the full spectrum of ocular manifestations in patients with Noonan 
syndrome (NS). 
Design
Prospective cross-sectional clinical and genetic study in a tertiary referral center.
Participants
Twenty-five patients with NS (mean age, 14 years; range, 8 months to 25 years), clinically 
diagnosed by validated criteria. 
Methods
All patients were examined by the same team following a detailed study protocol. 
Genetic analyses were performed in 23 patients.
Main Outcome Measures
Ocular abnormalities of vision and refraction, external ocular features, ocular position 
and motility, anterior segment, posterior segment, and intraocular pressure. 
Results
Ocular features of vision and refraction were amblyopia (32%), myopia (40%), and 
astigmatism (52%). External ocular features were epicanthic folds (84%), hypertelorism 
(68%), ptosis (56%), high upper eyelid crease (64%), lower eyelid retraction (60%), 
abnormal upward slanting palpebral fissures (36%), downward slanting palpebral 
fissures (32%), and lagophthalmos (28%). Orthoptic abnormalities included strabismus 
(40%), abnormal stereopsis (44%), and limited ocular motility (40%). Anterior segment 
abnormalities included prominent corneal nerves (72%) and posterior embryotoxon 
(32%). Additional ocular features were found, including non-glaucomatous optic disc 
excavation (20%), relatively low (< 10 mm Hg) intraocular pressure (22%), and optic 
nerve hypoplasia (4%). Mutations were established in 22 patients: 19 PTPN11 mutations 
(76%), one SOS1 mutation, one BRAF mutation and one KRAS mutation. The patient with 
the highest number of prominent corneal nerves had a SOS1 mutation. The patient 
with the lowest visual acuity, associated with bilateral optic nerve hypoplasia, had a 
BRAF mutation. Patients with severe ptosis and nearly total absence of levator muscle 
function had PTPN11 mutations. All patients showed at least three (range, 3-13; mean, 
7) ocular features, including at least one external ocular feature in more than 95 percent 
of the patients
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Conclusion
NS is a clinical diagnosis with multiple genetic bases, associated with an extensive 
variety of congenital ocular abnormalities. Ocular features of NS are characterized by 
one or more developmental anomalies of the eyelids (involving the position, opening 
and closure), associated with various other ocular abnormalities in childhood, including 
amblyopia, myopia, astigmatism, strabismus, limited ocular motility, prominent corneal 
nerves, and posterior embryotoxon.
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Introduction
Noonan syndrome (NS), first described by Noonan and Ehmke in 1963 (1), is an 
autosomal dominant syndrome characterized by facial dysmorphism, short stature 
and congenital heart defects (2,3). Distinctive other abnormalities of NS include mild 
learning problems, hearing impairment, hematologic anomalies, cryptorchidism and 
intrinsic ophthalmic abnormalities. There is a great diversity in the phenotypes. 
Incidence rates vary from 1:1000 to 1:2500 live births (4,5).
The first gene discovered to be responsible for NS was PTPN11 on chromosome 
12q24.1. This gene encodes the nonreceptor-type tyrosine phosphatase SHP-2, which 
implicates dysfunction of several signal transduction pathways and, therefore, 
influences various developmental processes. About 50 percent of the patients with NS 
have a PTPN11 mutation (6). SHP-2 is required for the function of the Ras/mitogen-
activated protein kinase (Ras/MAPK) pathway and is essential in the response to growth 
factors, cell adhesion molecules, cytokines and hormones (7). Mutations in other coding 
genes of proteins that are associated with function of the Ras/MAPK pathway are also 
found. KRAS mutations were described in 2006 (8), and SOS1 mutations were discovered 
in 2007 (9). Since then, studies have described BRAF, RAF1, SHOC2, NRAS, MAP2K1, 
MAP2K2, SOS2 and RIT1 mutations in NS (10-16).
In clinical reports, the main facial findings of NS are hypertelorism, downslanting 
palpebral fissures and ptosis (4,17), but few studies with in depth ophthalmologic 
examinations have been performed. In 1992, a study of 58 patients showed at least 
one ophthalmological abnormality in 95 percent of the patients (18). In a more recent 
study, all 35 patients with NS showed at least one abnormality (19). Although ocular 
abnormalities are described in up to 100% in all Noonan patients (5,18), few studies 
have reported comprehensively about these features. Complete ophthalmologic 
examinations for both external and inner ocular abnormalities in NS are rare. The aim 
of our study is to determine prospectively the full spectrum of ocular manifestations 
in patients with NS and link the phenotypes to the genotypes.
Patients and Methods
Protocol setup
Twenty-five patients with NS from the Departments of Genetics and Pediatrics, Radboud 
University Medical Center, Nijmegen, The Netherlands, were referred for prospective 
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and complete ophthalmologic examination in a detailed study protocol by a team of 
the Institute of Ophthalmology. The same team examined all the patients. Seventeen 
patients were male and eight were female. They were clinically diagnosed by the criteria 
of van der Burgt et al (20), including characteristic features in 6 categories (facial, 
cardiac, height, chest wall, family history, and other), with two alternatives (A, B) in each 
category. Definite NS: 1A plus one of 2A-6A or two of 2B-6B; 1B plus two of 2A-6A or 
three of 2B-6B. Age at ocular examination ranged from eight months to 25 years of 
age, with a mean age of 14 years. The cohort included 23 Caucasians, one Turkish and 
one Hindustani. Two brother and sister pairs were included. 
The ophthalmologic study protocol included a detailed ocular history and measurements 
in six ophthalmic categories: (1) vision and refraction, using subjective and objective 
methods; (2) external ocular features, including anthropometry and photography; (3) 
ocular position and motility, including full orthoptic testing; (4) anterior segment, including 
slit-lamp biomicroscopy; (5) posterior segment, including ophthalmoscopy; and (6) 
intraocular pressure, including tonometry. The study adhered to the tenets of the 
Declaration of Helsinki, and local ethics committee approval was obtained. All 
participants or their parents gave fully informed consent for performing the study and 
for publication of data, tables and photography of eye-strips.
Ocular Examination
A full ophthalmologic examination was performed. Best-corrected visual acuity (BCVA) 
was assessed with Snellen optotypes at six meters after subjective and objective 
refraction measurements, including keratometry. Refractive errors were defined to be 
clinically significant if the spherical equivalent of ametropia (SEA) was 1.00 or more 
diopters	(D).	They	were	classified	as	hyperopia	(positive	SEA;	absolute	value	of	SEA	≥	
1.00	D)	or	myopia	(negative	SEA;	absolute	value	of	SEA	≥	1.00	D),	and	astigmatism	
(absolute	value	of	astigmatism	≥	1.00	D).	Furthermore,	Amsler	grid	tests	and	Donders	
tests were performed.
Subjective scoring of the external ocular features was performed according to the 
methods of Farkas (21), and for the definition of ptosis we used the criteria of Small 
and coworkers (22). Levator function tests were performed with a ruler. Anthropometry 
was used for three objective measurements: the inner canthal distance (En-En), the 
outer canthal distance (Ex-Ex), and the interpupillary distance (PD).
Photogrammetric evaluation was done to complete the physical measurements and 
facial findings. In anthropometry and photogrammetry standard landmarks were used 
for measuring distances and angles based upon the literature of Farkas (21). For facial 
photography (Olympus Co., Tokyo, Japan), patients were positioned in a standard 
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ophthalmic headrest with an adjustable chin rest and forehead strap to ensure stable 
head position. Photographs were taken with the eyes in the primary position of gaze, 
with fixation of the camera lens at three meters. The indices were based upon Stengel-
Rutkowski and coworkers (23). Finally, Hertel exophthalmometry (Oculus Optikgeräte 
GmbH, Wetzlar, Germany) was performed.
The orthoptic examination included examination of ocular alignment with cover tests, 
with the patient fixation on an accommodative target at near (30 cm) and distance (2.5 
m and 6 m). Ocular motility was tested by checking the ocular ductions in the cardinal 
directions of gaze. Binocular vision tests were performed at 30 cm (prism test, Titmus 
stereotest), at 2.5 m (Bagolini test) and 6 m (Worth four dot test).
Ocular examinations were completed with testing of pupillary reactions, slit-lamp 
biomicroscopy (Haag-Streit AG, Bern, Switzerland), and measurement of intraocular 
pressure using non-contact tonometry (children) and applanation tonometry (adults). 
Ophthalmoscopy (indirect and direct) was performed after mydriasis. For children, the 
refraction was performed under cycloplegia after topical administration of 
cyclopentolate 1%. In a selected case we performed digital color fundus photography 
(Topcon, Tokyo, Japan) and spectral-domain optical coherence tomography (SD OCT; 
Heidelberg Engineering, Heidelberg, Germany). Ocular features of NS were defined as 
major ocular features (prevalence > 50%), minor ocular features (prevalence 25-50%), 
and additional ocular features (prevalence < 25%).
Genetic Analysis
Genetic analyses were performed in 23 patients by Sanger sequence analysis in routine 
DNA diagnostic setting for mutations in the coding regions of the genes known for NS. 
For primer sequences and PCR conditions we refer to previous studies from our 
medical center (24). Descriptive statistics with percentages are used for analyzing the 
results. We compared the ocular manifestations of our 25 patients with other cohort 
studies of NS (18,19,25,26).
Results
The individual ocular manifestations and genetic findings of the 25 patients with NS 
are summarized in Table 1. The ocular features of the present cohort are compared 
with other cohort studies in Table 2, which shows differences in the prevalence of 
ocular features and new findings.
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Ophthalmologic history
Eighteen patients (72%) had been seen by an ophthalmologist before their participation 
in this study. Eight patients (32%) had a history of occlusion therapy for amblyopia, 
because of congenital blepharoptosis or infantile strabismus. Three patients (12%) had 
a history of ptosis surgery and three other patients (12%) strabismus surgery. Thirteen 
patients (52%) used glasses for refractive errors.
Vision and refraction
Visual acuity measurements were performed in 24 patients; one patient was too young 
for reliable results. This patient without measurement showed no signs of visual 
impairment. Twenty-three patients had normal to near-normal corrected visual acuity. 
One patient who was visually impaired (Patient 19) had binocular best-corrected visual 
acuity of 0.3. Ophthalmologic examination revealed three ocular anomalies with a 
prevalence of more than 25%: treated and untreated amblyopia in eight patients (32%), 
myopia in 10 patients (40%), and astigmatism in 13 patients (52%). 
External ocular features
Ophthalmologic examination revealed five features with a prevalence of more than 
50% (major ocular features): epicanthic folds in 21 patients (84%), hypertelorism in 
17 patients (68%), ptosis in 14 patients (56%), high upper eyelid crease in 16 patients 
(64%), and lower eyelid retraction in 15 patients (60%). In 10 patients (40%) ptosis 
was asymmetrical (Figure 1A) and in five of them ptosis was unilateral. Lower eyelid 
retraction, with inferior scleral show in the primary position of gaze (Figure 1B), was 
most prominent on the lateral side. Ocular features with a prevalence of more than 
25% (minor ocular features) were: supra-normal (>5°) upslanting palpebral fissures 
in nine patients (36%) (Figure 1C), downslanting palpebral fissures in eight patients 
(32%), and incomplete eyelid closure, i.e. lagophthalmos, in seven patients (28%). 
Additional external ocular features were mild proptosis in one patient (Patient 17; 
Hertel exophthalmometry BE 20.5 mm), and one patient showed bilateral blepharitis 
(Patient 5).
Strabismus and ocular motility
Ophthalmic examinations revealed three minor ocular features (Table 2, category 3): 
strabismus in 10 patients (40%), absence of normal stereopsis in 11 patients (44%), and 
limited ocular motility in 10 patients (40%). Strabismus included exotropia in seven 
patients and esotropia in three patients. In the limited ocular motility group, nine had 
limited abduction (Figure 2), five had limited adduction, and two had limited elevation. 
None of the patients showed signs of congenital aberrant innervation of the extraocular 
muscles or pupils. There was no ocular retraction phenomenon on attempted adduction.
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Table 1. Major ocular manifestations and molecular genetic findings in 25 patients clinically diagnosed as Noonan 
Syndrome
Table 1. Continued
Patient Vision and Refraction External Ocular Features
Strabismus and Ocular 
Motility Anterior Segment Posterior Segment Genetic Findings
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No  RE LE ≥ 1D
1 F,11 1.0 1.0 No No Yes No BE No Upward No No No No BE No 0.3 10-10 PTPN11 c.922A>G p.N308D
2 M,13 0.8 1.0 No RE Yes RE (s) BE BE Normal BE No No BE  ≥10 BE No 0.7 11-13 PTPN11 c.922A>G p.N308D
3 M,7 1.0 1.0 No BE Yes BE BE LE Downward No No No BE  ≥10 No No <0.3 13-13 No genetic 
analysis
4 F,9 0.8 1.0 Astigmatism BE Yes BE BE BE Upward BE No No BE  ≥10 No No <0.3 12-12 PTPN11 c.236A>G p.Q79R
5 M,13 1.0 1.0 No BE No No BE BE Normal No Exotropia No No No No <0.3 12-12 PTPN11 c.236A>G p.Q79R
6 M,18 1.0 1.0 Myopia + astigmatism BE No No No BE Upward No No No BE <5 BE No <0.3 11-11 PTPN11 c.853T>C p.F285L
7 M,21 1.2 1.2 No BE No No No BE Downward No No No BE <5 No No 0.5 10-12 PTPN11 c.922A>G p.N308D
8 M,4 0.5 0.5 Myopia + astigmatism BE Yes No No No Downward No Exotropia (s) No BE <5 No No <0.3 NR No mutation 
identified
9 M,18 0.8 0.8 Myopia + astigmatism BE Yes No LE BE Normal No No BE (n) No BE No <0.3 9-10 PTPN11 c.922A>G p.N308D
10 F,19 1.0 1.0 Myopia + astigmatism No No No No No Normal No No No No BE No <0.3 10-10 PTPN11 c.922A>G p.N308D
11 M,10 1.0 1.0 Myopia BE Yes No No BE Normal BE Exotropia No BE <5 No No <0.3 14-14 PTPN11 c.1471C>T p.P491S
12 F,14 1.0 1.0 Myopia + astigmatism BE Yes LE LE BE Upward No Esotropia BE BE <5 No No <0.3 11-11 PTPN11 c.236A>G p.Q79R
13 M,16 1.2 1.2 No No No LE BE BE Normal BE No BE BE ≥5 No No <0.3 8-10 PTPN11 c.236A>G p.Q79R
14 M,20 0.6 0.5 Myopia + astigmatism BE Yes RE<LE BE No Normal No Esotropia BE BE ≥20 No TRV <0.3 10-12 SOS1 c.1644T>G p.S548A
15 M,18 1.0 0.8 Astigmatism BE No LE BE BE Downward No No BE BE  ≥10 No No <0.3 8-11 PTPN11 c.179G>C p.G60A
16 F,15 0.8 0.6 Myopia + astigmatism BE Yes BE (s) No No Upward BE No BE BE ≥5 No No 0.5 12-15 PTPN11 c.182A>G p.D61G
17 M,18 1.0 1.0 Astigmatism BE No BE BE BE Downward No No No BE  ≥10 No No <0.3 13-14 PTPN11 c.1510A>G p.M504V
18 M,11 1.0 1.0 No BE Yes No LE No Upward No No No BE ≥5 No No 0.5 8-12 PTPN11 c.922A>G p.N308D
19 M,17 0.1 0.3 Myopia + astigmatism BE Yes RE BE LE Upward No Esotropia (s) BE (n) BE  ≥10 No ONHH 0.3 18-20 BRAF c.730A>C p.T244P
20 M,15 0.3 0.5 No BE Yes No No No Downward No Exotropia No No No No 0.6 8-12 PTPN11 c.182A>G p.D61G
21 F,15 1.0 1.0 Myopia + astigmatism BE Yes BE (s) BE BE Downward BE No BE BE ≥5 No No <0.3 12-12 No genetic 
analysis
22 F,12 0.8 0.5 No BE Yes No No No Upward No Exotropia No BE <5 LE TRV <0.3 12-13 KRAS c.40G>A p.V14I
23 M,0 NVC NVC No BE Yes RE BE No Downward BE No No No BE No <0.3 NR PTPN11 c.1504T>A p.S502T
24 M,25 0.5 0.8 Hyperopia +  
astigmatism
No No RE No No Upward No Esotropia (s) BE BE ≥5 No No <0.3 10-11 PTPN11 c.1510A>G p.M504V
25 F,12 1.0 1.0 No BE Yes LE BE BE Normal No Exotropia BE No RE No <0.3 10-12 PTPN11 c.181G>A p.D61N
Additional findings: (n) = nystagmus; (s) = after surgery; BE = both eyes; C/D = cup/disk; F = female; LE = left eye; 
M = male; No = feature absent; NR = feature not examined; NVC = normal visual contact; ONH = optic nerve head; 
ONHH = ONH hypoplasia; RE = right eye; SEA = spherical equivalent of ametropia; TRV = tortuous retinal vessels.
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Table 1. Major ocular manifestations and molecular genetic findings in 25 patients clinically diagnosed as Noonan 
Syndrome
Table 1. Continued
Patient Vision and Refraction External Ocular Features
Strabismus and Ocular 
Motility Anterior Segment Posterior Segment Genetic Findings
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No  RE LE ≥ 1D
1 F,11 1.0 1.0 No No Yes No BE No Upward No No No No BE No 0.3 10-10 PTPN11 c.922A>G p.N308D
2 M,13 0.8 1.0 No RE Yes RE (s) BE BE Normal BE No No BE  ≥10 BE No 0.7 11-13 PTPN11 c.922A>G p.N308D
3 M,7 1.0 1.0 No BE Yes BE BE LE Downward No No No BE  ≥10 No No <0.3 13-13 No genetic 
analysis
4 F,9 0.8 1.0 Astigmatism BE Yes BE BE BE Upward BE No No BE  ≥10 No No <0.3 12-12 PTPN11 c.236A>G p.Q79R
5 M,13 1.0 1.0 No BE No No BE BE Normal No Exotropia No No No No <0.3 12-12 PTPN11 c.236A>G p.Q79R
6 M,18 1.0 1.0 Myopia + astigmatism BE No No No BE Upward No No No BE <5 BE No <0.3 11-11 PTPN11 c.853T>C p.F285L
7 M,21 1.2 1.2 No BE No No No BE Downward No No No BE <5 No No 0.5 10-12 PTPN11 c.922A>G p.N308D
8 M,4 0.5 0.5 Myopia + astigmatism BE Yes No No No Downward No Exotropia (s) No BE <5 No No <0.3 NR No mutation 
identified
9 M,18 0.8 0.8 Myopia + astigmatism BE Yes No LE BE Normal No No BE (n) No BE No <0.3 9-10 PTPN11 c.922A>G p.N308D
10 F,19 1.0 1.0 Myopia + astigmatism No No No No No Normal No No No No BE No <0.3 10-10 PTPN11 c.922A>G p.N308D
11 M,10 1.0 1.0 Myopia BE Yes No No BE Normal BE Exotropia No BE <5 No No <0.3 14-14 PTPN11 c.1471C>T p.P491S
12 F,14 1.0 1.0 Myopia + astigmatism BE Yes LE LE BE Upward No Esotropia BE BE <5 No No <0.3 11-11 PTPN11 c.236A>G p.Q79R
13 M,16 1.2 1.2 No No No LE BE BE Normal BE No BE BE ≥5 No No <0.3 8-10 PTPN11 c.236A>G p.Q79R
14 M,20 0.6 0.5 Myopia + astigmatism BE Yes RE<LE BE No Normal No Esotropia BE BE ≥20 No TRV <0.3 10-12 SOS1 c.1644T>G p.S548A
15 M,18 1.0 0.8 Astigmatism BE No LE BE BE Downward No No BE BE  ≥10 No No <0.3 8-11 PTPN11 c.179G>C p.G60A
16 F,15 0.8 0.6 Myopia + astigmatism BE Yes BE (s) No No Upward BE No BE BE ≥5 No No 0.5 12-15 PTPN11 c.182A>G p.D61G
17 M,18 1.0 1.0 Astigmatism BE No BE BE BE Downward No No No BE  ≥10 No No <0.3 13-14 PTPN11 c.1510A>G p.M504V
18 M,11 1.0 1.0 No BE Yes No LE No Upward No No No BE ≥5 No No 0.5 8-12 PTPN11 c.922A>G p.N308D
19 M,17 0.1 0.3 Myopia + astigmatism BE Yes RE BE LE Upward No Esotropia (s) BE (n) BE  ≥10 No ONHH 0.3 18-20 BRAF c.730A>C p.T244P
20 M,15 0.3 0.5 No BE Yes No No No Downward No Exotropia No No No No 0.6 8-12 PTPN11 c.182A>G p.D61G
21 F,15 1.0 1.0 Myopia + astigmatism BE Yes BE (s) BE BE Downward BE No BE BE ≥5 No No <0.3 12-12 No genetic 
analysis
22 F,12 0.8 0.5 No BE Yes No No No Upward No Exotropia No BE <5 LE TRV <0.3 12-13 KRAS c.40G>A p.V14I
23 M,0 NVC NVC No BE Yes RE BE No Downward BE No No No BE No <0.3 NR PTPN11 c.1504T>A p.S502T
24 M,25 0.5 0.8 Hyperopia +  
astigmatism
No No RE No No Upward No Esotropia (s) BE BE ≥5 No No <0.3 10-11 PTPN11 c.1510A>G p.M504V
25 F,12 1.0 1.0 No BE Yes LE BE BE Normal No Exotropia BE No RE No <0.3 10-12 PTPN11 c.181G>A p.D61N
Additional findings: (n) = nystagmus; (s) = after surgery; BE = both eyes; C/D = cup/disk; F = female; LE = left eye; 
M = male; No = feature absent; NR = feature not examined; NVC = normal visual contact; ONH = optic nerve head; 
ONHH = ONH hypoplasia; RE = right eye; SEA = spherical equivalent of ametropia; TRV = tortuous retinal vessels.
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Table 2.  Ocular Manifestations of Noonan Syndrome. Present Study Compared with the Literature 
Ocular features Literature Present study
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1. Vision and Refraction       
Amblyopia 18/55  (33) 3/10  (30) NR NR 21/65  (32) 8/25  (32)
Visually impaired (BCVA < 0.3) 2/55  (4) 0/10  (0) NR NR 2/65  (3) 1/25  (4)
Refraction anomaly (SEA ≥ 1 D) 33/57  (58) 7/10  (70) 9/18  (50) NR 49/85  (58) 14/25  (56)
     Myopia 8/57 (14) NR 4/18  (22) NR 12/75  (16) 10/25  (40)*
     Hyperopia 20/57  (35) NR 4/18  (22) NR 24/75  (32) 1/25  (4)*
     Astigmatism (≥ 1 D) 21/57  (37) 7/10  (70) 3/18  (17) NR 31/85  (36) 13/25  (52)
2. External Ocular Features       
Epicanthic folds 22/56  (39)   5/10  (50) NR NR 27/66  (41) 21/25  (84)*
     Mild NR NR NR NR NR 15/25  (60)*
     Moderate or severe NR NR NR NR NR 6/25  (24)*
Hypertelorism 43/58  (74) 2/10  (20) NR 20/35  (57) 65/103  (63) 17/25  (68)
Ptosis 27/56 (48) 3/10  (30) 2/18  (11) 18/35  (51) 50/119  (42) 14/25  (56)*
     Levator function < 10 mm NR NR NR NR NR 5/25 (20)*
     Levator function < 5 mm NR NR NR NR NR 3/25 (12)*
     Bilateral NR 2/10  (20) 1/18  (6) NR 3/28  (11) 9/25  (36)*
     Unilateral NR 1/10  (10) 1/18  (6) NR 2/28  (7) 5/25  (20)*
     RE/LE asymmetry NR 1/10  (10) 1/18  (6) NR 2/28  (7) 10/25  (40)*
     Ptosis surgery 3/58  (5%) 2/10  (20) NR NR 5/68 (7) 3/25  (12)
High upper eyelid crease NR NR NR NR NR 16/25 (64)*
Lower eyelid retraction 2/56  (4) NR NR NR 2/56  (4) 15/25  (60)*
Slanting palpebral fissures
     Upward slanting (> 5°) 4/58  (7) NR NR NR 4/58  (7) 9/25  (36)*
     Normal range (0-5°) 32/58  (55) NR NR NR 32/58  (55) 8/25  (32)
     Downward slanting (< 0°) 22/58  (38) 6/10  (60) NR 26/35  (74) 54/103 (52) 8/25  (32)*
Lagophthalmos (incomplete closure) NR NR NR NR NR 7/25  (28)*
Proptosis 1/56  (2) NR 1/18  (6) 9/35  (26) 11/109  (10) 1/25  (4)*
Orbital dermoid cyst NR 1/10  (10) NR NR 1/10  (10) 0/25  (0)
Nasolacrimal duct obstruction 1/56  (2) 2/10  (20) NR NR 3/66  (5) 0/25  (0)
3. Strabismus and Ocular Motility       
Strabismus 28/58  (48) 6/10  (60) 12/18  (67) 5/35  (14) 51/121 (42) 10/25  (40)
     Esotropia 13/58  (22) 3/10  (30) 3/18  (17) 3/35  (8) 22/121  (18) 3/25  (12)
     Exotropia 10/58  (17) 3/10  (30) 9/18  (50 2/35  (6) 24/121  (20) 7/25  (28)
     Vertical 4/58  (7) 0/10  (0) 0/18  (0) 0/35  (0) 4/121  (3) 0/25  (0)
     Mixed 1/58  (2) 0/10  (0) 0/18  (0) 0/35  (0) 1/121  (1) 0/25  (0)
     Strabismus surgery 5/58  (9) 3/10  (30) NR NR 8/68  (12) 3/25  (12)
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Ocular features Literature Present study
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Abnormal stereopsis 21/58  (36) NR 15/18  (83) NR 36/76  (47) 11/25  (44)
Limited ocular motility NR NR 11/18  (61) NR 11/18  (61) 10/25  (40)*
Head turn (ocular torticollis) 1/58  (2) NR NR NR 1/58  (2) 1/25  (4)
Nystagmus 5/58  (9) 2/10  (20) 5/18  (28) 0/35  (0) 12/121  (10) 2/25  (8)
4. Anterior Segment     
Prominent corneal nerves BE 22/48  (46) NR NR 18/35  (51) 40/83  (48) 18/25  (72)*
     ≥ 10 / eye 13/48  (27) NR NR NR 13/48  (27) 7/25  (28)
Posterior embryotoxon NR NR NR 1/35  (3) 1/35  (3) 8/25  (32)*
Microcornea 0/48  (0) NR NR 1/35  (3) 1/83  (1) 0/25  (0)
Keratoconus NR NR NR NR NR 0/25  (0)
Corneal opacities 4/48  (8) NR NR 1/35  (3) 5/83  (6) 0/25  (0)
Persistent pupillary membrane 1/48  (2) NR NR 0/35  (0) 1/48  (2) 0/25  (0)
Iris coloboma or transillumination 0/53  (0) NR NR 0/35  (0) 0/88  (0) 0/25  (0)
Cataract 1/53  (2) NR NR 0/35  (0) 1/88  (1) 0/25  (0)
Lens vacuoles 3/53  (6) NR NR 0/35  (0) 3/83  (3) 0/25  (0)
Uveitis 1/48  (2) NR NR 0/35  (0) 1/83  (1) 0/25  (0)
Dilated episcleral vessels 0/48  (0) NR NR 1/35  (3) 1/83  (1) 0/25  (0)
5. Posterior Segment       
Optic nerve head malformation 6/51  (12) 2/10  (20) 2/18  (11) 1/35  (3) 11/114  (10) 6/25  (24)
     Excavation (C/D ratio ≥ 0.5) NR 1/10  (10) 2/18  (11) 1/35  (3) 4/63  (6) 5/25  (20)*
     Coloboma 2/51  (4) 0/10  (0) 0/18  (0) 0/35  (0) 2/114  (2) 0/25  (0)
     Swelling/Drusen 2/51  (4) 0/10  (0) 0/18  (0) 0/35  (0) 2/114  (2) 0/25  (0)
     Hypoplasia 2/51  (4) 0/10  (0) 0/18  (0) 0/35  (0) 2/114  (2) 1/25  (4)
     Optic pit 0/51  (0) 1/10  (10) 0/18  (0) 0/35  (0) 1/114  (1) 0/25  (0)
Optic nerve head paleness 0/51  (0) 2/10  (20) 1/18  (6) 0/35  (0) 3/114  (3) 0/25  (0)
Myelinated nerve fibers 1/51  (2) NR 0/18  (0) 0/35  (0) 1/104  (1) 0/25  (0)
Maculopathy 0/51  (0) NR NR 0/35  (0) 0/86  (0) 0/25  (0)
Tortuous retinal vessels 3/51  (6) NR NR 0/35  (0) 3/86  (3) 2/25  (8)
Angioid streaks 0/51  (0) 1/10  (10) NR 0/35  (0) 1/96  (1) 0/25  (0)
Myopic fundus degeneration 0/51  (0) NR NR 2/35  (6) 2/86  (2) 0/25  (0)
Coloboma of the retina and choroid 0/51  (0) NR NR 0/35  (0) 0/86  (0) 0/25  (0)
Posterior vitreous detachment NR NR NR 1/35  (3) 1/35  (3) 0/25  (0)
6. Intraocular Pressure       
Low IOP (< 10 mm Hg) NR NR NR NR NR 5/23  (22)*
High IOP (> 21 mm Hg) NR NR NR NR NR 0/23  (0)
Glaucoma NR NR NR NR NR 0/23  (0)
0 = feature not present; BCVA = best corrected visual acuity; BE = both eyes; C/D ratio = cup-to-disc ratio; IOP = intraocular pressure; NR 
= not recorded or examined; SEA = spherical equivalent of ametropia; * = remarkable difference.
Table 2. Continued
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One patient (Patient 7), who showed normal ocular alignment at distance and near (30 
cm), did not exhibit stereopsis with reading because of V-pattern esotropia with 
suppression in downgaze. Nystagmus was found in two patients (8%); one of them 
(Patient 19) had poor vision and infantile sensory nystagmus.
Anterior segment
Ophthalmologic examination with slit-lamp biomicroscopy (Table 2, category 4) showed 
two corneal features: prominent corneal nerves (Figure 3) in 18 patients (72%) and 
posterior embryotoxon (anteriorly displaced Schwalbe line at the corneal limbus) 
(Figure 4) in eight patients (32%). The number of clearly visible corneal nerves varied 
between only one pair to more than 20 visible nerves in both eyes. In two patients 
(Patient 6 and Patient 23, Table 1) an asymmetric number of visible nerves between 
the two eyes was found. The posterior embryotoxon was located temporally in four 
patients and both temporally and nasally in the other four patients. There were no 
other abnormalities discovered with slit-lamp examination.
Posterior segment
Ocular examinations in the categories 5 and 6 (Table 2), showed additional ocular 
features with a prevalence of less than 25%: non-glaucomatous optic disc excavation 
(cup-to-disc ratio of 0.5 or more) in five patients (20%) and bilateral optic nerve 
hypoplasia in one patient (4%) (Figure 5). Two patients (8%) showed tortuous retinal 
vessels. No other relevant ophthalmoscopic features were found.
Figure 1. External ocular manifestations of Noonan syndrome (NS). 
A, left column: Examples of ptosis asymmetry; note the difference between the right eye and the left eye (Patients 2, 
12, and 15). B, middle column: Examples of lower eyelid retraction; note inferior scleral show in the primary position of 
gaze (Patients 6, 9, and 13). C, right column: Examples of upward slanting palpebral fissures; note that abnormal slanting 
palpebral fissures in NS are not always downward (Patients 4, 16, and 18). Photographs were taken under standardized 
conditions, with permission for publication. 
A B C
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Intraocular pressure
Intraocular pressure was measured and relatively low (< 10 mm Hg) intraocular 
pressure was found in five of 23 examined patients (22%). None of the patients were 
found to have ocular hypertension or glaucoma.
Genotype
Genetic analyses were performed in 23 patients. Mutations were found in 22 patients 
(Table 1): 19 patients had a PTPN11 mutation (76%). The three other patients revealed, 
respectively, a SOS1 mutation, a BRAF mutation and a KRAS mutation. Within the PTPN11 
gene mutations, the c.922A>G was the most common mutation occurring in six patients. 
Patient numbers 4 and 5, and 12 and 13 were sister and brother pairs. The c.236A>G 
changes were found within these two families (Table 1). 
Ocular phenotype-genotype correlation
In the three single mutations described in our cohort, respectively SOS1, BRAF and 
KRAS mutation, different ocular manifestations as compared to PTPN11 mutations 
were found. The patient with the BRAF mutation (Patient 19) had poor vision, infantile 
sensory nystagmus, strabismus and bilateral optic nerve hypoplasia. He was the only 
patient in our NS cohort who was severely visually impaired. The patient with the KRAS 
mutation (Patient 22) had the highest hypertelorism index (En-En/Zy-Zy), and the 
patient with the SOS1 mutation (Patient 14) showed the highest number of prominent 
corneal nerves and severe ptosis with a relatively good levator muscle function. In 
patients with PTPN11 mutations, a variety of all different ocular abnormalities was 
found (Table 1). 
Figure 2. Limited ocular motility of patient 19.
Abduction deficit ODS in (A) maximal gaze to the right, and (B) maximal gaze to the left.
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Discussion 
Our prospective observational study shows that young patients with genetically-
established NS have a variety of multiple ocular manifestations, including external ocular 
abnormalities, abnormalities of vision and refraction, of ocular position and motility, 
and of the anterior ocular segment. Abnormalities of the posterior ocular segment and 
intraocular pressure are less-frequently present. All our NS patients showed mutations 
that were previously described (6-11), and we have found no new variants (ClinVar 
database of the National Center for Biotechnology Information, http://www.ncbi.nlm.
nih.gov/ClinVar, accessed June 2016). As NS is a clinical diagnosis with multiple genes 
and different mutations causing the phenotype, the ocular manifestations would be 
expected to reflect the specific mutated gene. More severe variants of ocular 
manifestations were found in our patients with a SOS1 mutation (highest number of 
prominent corneal nerves), and with a BRAF mutation (lowest visual acuity, with optic 
nerve hypoplasia). In NS, prominent corneal nerves are only described in patients with 
PTPN11 mutations (19), and in patients without genetic analysis (18). SOS1 mutations 
are not linked to prominent corneal nerves before. The study of Alfieri et al (26), including 
ten NS patients with PTPN11, three with RAF1 and five with SOS1 mutations, did not 
report results of anterior segment examination. With few reports of individuals with NS 
and specific mutations, phenotype-genotype correlations are difficult. Ocular 
manifestations in our cohort mainly represent patients with PTPN11 mutations. 
Figure 3. Bilateral prominent corneal nerves of patient 14.
(A) near the corneal limbus, and (B) more centrally.
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Our study shows some differences with earlier cohort studies of NS (18,19,25,26). In 
our patients, astigmatism and myopia were common findings, but not hyperopia as 
compared to the studies of Lee et al and Alfieri et al (26). We found epicanthic folds to 
be the most common abnormality, but we also included mild cases of epicanthic folds. 
We found a higher prevalence of ptosis as compared to previous studies (18,19,25,26). 
In previous reports symmetrical ptosis was evident. However, we found a marked 
asymmetry between the right and left eye as a characteristic manifestation of NS. 
Although palpebral fissures of patients with NS are described to be characteristically 
downward slanting (18,19,25). we found an equal number of patients with abnormal 
upward slanting palpebral fissures, which is a new ocular manifestation. 
Marin et al described 35 patients with PTPN11 mutations, (19) with downward slanting 
palpebral fissures as their most frequent finding in 74 percent of the patients. They 
also described a high percentage of proptosis (26%), where we only could confirm mild 
proptosis in one patient with Hertel exophthalmometry. They found no cases of 
nystagmus and hypothesize that nystagmus is more frequent in individuals with SOS1 
gene mutations (19). We found nystagmus in two patients: one with a BRAF mutation 
and one with PTPN11 mutation.
Figure 4. Posterior embryotoxon (Patient 6)
Slit-lamp image of the corneal limbus of the right eye showing the anteriorly displaced Schwalbe line (arrows), 
(A) temporally and (B) nasally.
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We report several ocular manifestations of NS that to date are uncommonly reported 
in the literature. These include asymmetry of ptosis, high upper eyelid crease, lower 
eyelid retraction (18), upward-slanting palpebral fissures, incomplete eyelid closure 
(lagophthalmos), limited ocular motility (26), prominent corneal nerves (18,19), and 
posterior embryotoxon (19). Recently, a NS patient with Axenfeld anomaly and PTPN11 
Figure 5. Fundus photography and spectral-domain optical coherence tomography (SD OCT) of a patient 
diagnosed as bilateral optic nerve hypoplasia (ONH), with bilateral poor vision since infancy, infantile 
sensory nystagmus, negative pattern-reversal visual-evoked potentials, weak flash visual-evoked 
potentials, red-green color vision defect, strabismus, high myopia and astigmatism (Patient 19, Table 1).
(A, C) Fundus images show relatively small optic discs with central cups, and (A) extorsion of the right fundus image due 
to excyclotropia. (B, D) SD OCT shows deep optic cups, with a horizontal disc diameter, defined as the distance between 
the edges of retinal pigment epithelium, of (B) RE 1090 μm and (D) LE 1200 μm. Horizontal cup diameter was RE 480 μm 
and LE 600 μm. The values of disc size and cup size fit in the range of patients with ONH, although cup depth of more 
than 400 μm is rather unusual for ONH (38).
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mutation was reported (29). SHP-2 plays an important role in the Ras/MAPK pathway 
and is postulated to play a role in the neural crest cell differentiation (29,30). Disruption 
in this signaling pathway is linked to craniofacial abnormalities and more specific to 
the development of the anterior segment of the eye (29). Some ocular abnormalities 
attributed to NS are only described in case reports (31-36), but were not found in our 
or other cohort studies (18,19,25,26). These ocular abnormalities, including keratoconus 
(31), colobomas (32,33), spontaneous corneal rupture (34), pupillary block glaucoma 
caused by anterior dislocation of the lens (35), and acute angle closure induced by 
pharmacologic mydriasis (36), are probably less common manifestations of NS.
The high prevalence of ocular abnormalities in NS, including amblyogenic factors such 
as ptosis, strabismus and astigmatism, makes it necessary to perform ocular 
examinations in the first years of life. Our study shows that patients with NS due to 
PTPN mutations generally have a good visual prognosis. We speculate that severe visual 
impairment in NS might be associated with a BRAF mutation, based on our single BRAF 
mutation patient with poor vision since infancy due to optic nerve hypoplasia. In similar 
visually impaired NS patients of Lee et al (18), no DNA studies were performed. More 
recently, hypoplastic or dysplastic optic nerves were found in a significant proportion 
(9 out of 20) of individuals with BRAF mutation in cardio-facio-cutaneous syndrome (37).
We found that some more extreme variants of the ocular manifestations of NS were 
associated with different mutations, e.g., most severe ptosis with PTPN11, lowest visual 
acuity with BRAF, highest number of corneal nerves with SOS1, highest hypertelorism 
index with KRAS. However, the number of patients is too low to draw conclusions about 
a possible ocular phenotype-genotype correlation. All patients in the present study 
showed at least three (range, 3-13; mean, 7) ocular features of NS, including at least 
one external ocular feature in more than 95 percent of the cases.
In conclusion, NS is a clinical diagnosis with multiple genetic bases, associated with an 
extensive variety of congenital ocular abnormalities. Ocular features of NS are 
characterized by one or more developmental anomalies of the eyelids (hypertelorism, 
epicanthic folds, ptosis, high upper eyelid crease, lower eyelid retraction, incomplete 
eyelid closure, and abnormal slanting palpebral fissures), associated with other ocular 
abnormalities in childhood (amblyopia, myopia, astigmatism, strabismus, limited ocular 
motility, prominent corneal nerves, and posterior embryotoxon).
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   55 24-09-18   08:45
CHAPTER 3
56    
References
1. Noonan JA, Ehmke DA. Associated noncardiac malformations in children with congenital 
heart disease. J Pediatrics 1963;63:468-70.
2. Allanson JE. Noonan syndrome. J Med Genet 1987;24:9-13.
3. van der Burgt I. Noonan syndrome. Orphanet J Rare Dis 2007;2:4.
4. Nora JJ, Nora AH, Sinha AK, et al. The Ullrich-Noonan syndrome (Turner phenotype). Am J 
Dis Child 1974;127:48-55.
5. Mendez HM, Opitz JM. Noonan syndrome: a review. Am J Med Genet 1985;21:493-506.
6. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein 
tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465-8.
7. Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 mutations in Noonan syndrome: molecular 
spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum 
Genet 2002;70:1555-63.
8.	 Carta	C,	Pantaleoni	F,	Bocchinfuso	G,	et	al.	Germline	missense	mutations	affecting	KRAS	
isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 
2006;79:129-35.
9. Tartaglia M, Pennacchio LA, Zhao C, et al. Gain-of-function SOS1 mutations cause a 
distinctive form of Noonan syndrome. Nat Genet 2007;39:75-9. 
10. Razzaque MA, Nishizawa T, Komoike Y, et al. Germline gain-of-function mutations in RAF1 
cause Noonan syndrome. Nat Genet 2007;39:1013-7.
11.  Niihori T, Aoki Y, Narumi Y, et al. Germline KRAS and BRAF mutations in cardio-facio-
cutaneous syndrome. Nat Genet 2006;38:294-6.
12. Cordeddu V, Di Schiavi E, Pennacchio LA, et al. Mutation of SHOC2 promotes aberrant 
protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat 
Genet 2009;41:1022-6.
13. Cirstea IC, Kutsche K, Dvorsky R, et al. A restricted spectrum of NRAS mutations causes 
Noonan syndrome. Nat Genet 2010;42:27-9.
14. Nava C, Hanna N, Michot C, et al. Cardio-facio-cutaneous and Noonan syndromes due to 
mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and 
overlap with Costello syndrome. J Med Genet 2007;44:763-71.
15.	 Cordeddu	V,	Yin	JC,	Gunnarsson	C,	et	al.	Activating	mutations	affecting	the	Dbl	homology	
domain of SOS2 cause Noonan syndrome. Hum Mutat 2015;36:1080-7.
16. Aoki Y, Niihori T, Banjo T, et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, 
a RAS/MAPK pathway syndrome. Am J Hum Genet 2013;93:173-80.
17. Noonan JA. Noonan syndrome. An update and review for the primary pediatrician. Clin 
Pediatr 1994;33:548-55.
18. Lee NB, Kelly L, Sharland M. Ocular manifestations of Noonan syndrome. Eye (Lond) 
1992;6:328-34.
19. Marin LR, da Silva FT, de Sá LC, et al. Ocular manifestations of Noonan syndrome. Ophthalmic 
Genet 2012;33:1-5.
20. van der Burgt I, Berends E, Lommen E, et al. Clinical and molecular studies in a large Dutch 
family with Noonan syndrome. Am J Med Genet 1994;53:187-91.
21. Farkas LG, Anthropometry of the head and face. 2nd ed. New York: Raven Press; 1994.
22.	 Small	RG,	Sabates	NR,	Burrows	D.	The	measurement	and	definition	of	ptosis.	Ophthal	Plast	
Reconstr Surg 1989;5:171-5.
23.	 Stengel-Rutkowski	 S,	 Schimanek	 P,	 Wernheimer	 A.	 Anthropometric	 definitions	 of	
dysmorphic facial signs. Hum Genet 1984;67:272-95.
24. Croonen EA, Nillesen W, Schrander C, et al. Noonan syndrome: comparing mutation-
positive with mutation-negative Dutch patients. Mol Syndromol 2013;4:227-34.
25. Reynolds DJ, Rubin SE, Fox J, Kodsi SR. Ocular manifestations of Noonan syndrome in the 
pediatric patient. J AAPOS 2004;8:282-3.
26.	 Alfieri	P,	Cesarini	L,	Zampino	G,	et	al.	Visual	function	in	Noonan	and	LEOPARD	syndrome.	
Neuropediatrics 2008;39:335-40.
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   56 24-09-18   08:45
57
OCULAR MANIFESTATIONS OF NOONAN SYNDROME: A PROSPECTIVE STUDY OF 25 PATIENTS
3
27.	 Hill	 V,	 Griffiths	 W,	 Kerr-Muir	 M,	 Hardman-Lea	 S.	 Non-bullous	 congenital	 ichtyosiform	
erythroderma, with ocular albinism and Noonan syndrome. Clin Exp Dermatol 2000;25:611-
4.
28. Schwartz DE. Noonan’s syndrome associated with ocular abnormalities. Am J Ophthalmol 
1972;73:955-60.
29. Guerin A, So J, Mireskandari K, et al. Expanding the clinical spectrum of ocular anomalies in 
Noonan syndrome: Axenfeld-anomaly in a child with PTPN11 mutation. Am J Med Genet A 
2015;167A:403-6.
30. Hashida N, Ping X, Nishida K. MAPK activation in mature cataract associated with Noonan 
syndrome. BMC Ophthalmol 2013:13:70.
31. Ascaso FJ, Del Buey MA, Huerva V, et al. Noonan’s syndrome with keratoconus and optic disc 
coloboma. Eur J Ophthalmol 1993;3:101-3.
32. Kleanthous L, Cruz D, D’Graham E, Efthimiou J. Colobomata associated with Noonan’s 
syndrome. Postgrad Med J 1987;63:559-61
33. Verloes A. Iris coloboma, ptosis, hypertelorism, and mental retardation: Baraitser-Winter 
syndrome or Noonan syndrome? J Med Genet 1993;30:425-6.
34. Au YK, Collins WP, Patel JS, Asamoah A. Spontaneous corneal rupture in Noonan syndrome. 
A case report. Ophthamic Genet 1997;18:39-41.
35. Mukhopadhyaya U, Chakraborti C, Mondal A, et al. Spontaneous dislocation of a crystalline 
lens to the anterior chamber with pupillary block glaucoma in Noonan syndrome: a case 
report. Pan Afr Med J 2014;17:135.
36. Padrón-Pérez N, Sanz-Moreno S, Lillo-Sopena J, Arruga J. Noonan syndrome with bilateral 
acute angle-closure. Clin Experiment Ophthalmol 2015;43:90-2.
37. Armour CM, Allanson JE. Further delineation of cardio-facio-cutaneous syndrome: clinical 
features of 38 individuals with proven mutations. J Med Genet 2008;45:249-54.
38. Pilat A, Sibley D, McLean RJ, et al. High-resolution imaging of the optic nerve and retina in 
optic nerve hypoplasia. Ophthalmol 2015;122:1330-9.
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   57 24-09-18   08:45
Ocular findings in Noonan syndrome: 
a retrospective cohort study of 105 patients
Dorothée C. van Trier, Ineke van der Burgt, Renske W. Draaijer, 
Johannes R. M. Cruysberg, Cees Noordam, Jos M. Draaisma
4
European Journal of Pediatrics. 2018:177;1293-1298
Ocular findings in No nan syndrome: 
a retrospective cohort study of 105 patients
Dor thée C. van Trier, Inek  van der Burgt, Renske W. Draaijer, 
Johannes R. M. Cruysberg, Cees Noordam, Jos M. Draaisma
European Journal of Pediatrics. 2018:177;1293-1298
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   58 24-09-18   08:45
Ocular findings in Noonan syndrome: 
a retrospective cohort study of 105 patients
Dorothée C. van Trier, Ineke van der Burgt, Renske W. Draaijer, 
Johannes R. M. Cruysberg, Cees Noordam, Jos M. Draaisma
4
European Journal of Pediatrics. 2018:177;1293-1298
Ocular findings in No nan syndrome: 
a retrospective cohort study of 105 patients
Dor thée C. van Trier, Inek  van der Burgt, Renske W. Draaijer, 
Johannes R. M. Cruysberg, Cees Noordam, Jos M. Draaisma
European Journal of Pediatrics. 2018:177;1293-1298
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   59 24-09-18   08:45
CHAPTER 4
60    
Abstract
The aim of this retrospective study is to describe ocular findings in a large Noonan 
syndrome cohort and to detect associations between ocular features and genetic 
mutations that were not found in earlier studies. We collected ophthalmological and 
genetic	data	of	105	patients	 (median	age,	12 years;	 range,	0–60 years)	clinically	
diagnosed as Noonan syndrome. The ocular findings were linked to the genotypes. All 
patients with Noonan syndrome showed multiple abnormalities in the categories of 
vision and refraction, external ocular features, ocular alignment and motility, anterior 
ocular segment, and posterior ocular segment. In total, 50 patients have NS due to a 
mutation	in PTPN11. Permanent visual impairment (bilateral best-corrected visual acuity 
< 0.3)	was	found	in	7	patients,	including	patients	with	a	mutation	in RAF1, SHOC2, 
and KRAS.	Keratoconus	was	found	in	2 PTPN11 positive	patients,	and	prominent	corneal	
nerves	were	observed	in	a	patient	with	a SOS1 mutation.	
Conclusions
This study shows an overview of ocular abnormalities in Noonan syndrome, including 
permanent visual impairment caused by binocular optic nerve abnormalities and 
nystagmus. Delay in ophthalmological diagnosis is still present, also in patients with 
visual impairment. All Noonan syndrome patients should have a complete 
ophthalmological examination at the time of diagnosis.
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Introduction
Noonan syndrome (NS) is an autosomal dominant disorder with a great variety in 
phenotype. Characteristics described with high frequency include short stature, 
congenital heart defects, face dysmorphology, and mild developmental delay. Other 
manifestations are cryptorchidism in males, chest wall abnormalities and 
ophthalmological abnormalities (19). NS belongs to the Rasopathies. Different 
mutations in coding genes leading to dysregulation of the Ras/mitogen-activated 
protein	kinase	pathway	can	cause	NS.	The	first	gene	discovered	was PTPN11 on	
chromosome	 12q24.1	 (17).	 Gain-of-function	mutations	 in PTPN11  are	 found	 in	
approximately 50% of the NS patients (18). At the moment, more than 14 genes 
responsible	for	NS	are	elucidated,	most	frequent PTPN11 (50%), SOS1 (10–13%),	and	
other	 less	 frequent	 genes	 including  KRAS,  RAF1,	 and  RIT1  (4,11,14,16).	 Facial	
dysmorphology is one of the major used clinical criteria for NS (19) and external ocular 
abnormalities (including hypertelorism, epicanthic folds, ptosis, and downslanting 
palpebral fissures) play an important role in facial characteristics. Besides the external 
ocular manifestations, other ocular manifestations occur and the results of ophthalmic 
examinations in NS are described briefly. The first cohort is described in 1992 with 
ophthalmological examinations in 58 patients (8). Few other studies report on ocular 
examinations (1,10,12) and the most recent study is a prospective ocular examination 
performed in our tertiary referral center in 25 patients that shows at least three ocular 
features in more than 95% of NS patients (20). In the international NS clinical 
management guidelines, referral to an ophthalmologist for assessment at the point 
of diagnosis is recommended (9,13,15). To give a more extensive overview of 
ophthalmological abnormalities and ocular problems in NS patients, we collected 
ophthalmological data in a large retrospective cohort.
Materials and methods
We collected retrospective data in a NS population at the Radboud University Medical 
Center in the Netherlands. All patients were clinically diagnosed, fulfilling the Van der 
Burgt criteria (19). In total, 201 patients were asked for informed consent and 128 
responded and gave permission for the use of their data. All available ophthalmological, 
pediatric, and genetic data of the participating patients were collected and used. 
Children	were	defined	as	younger	than	18 years	old.	Patients	without	available	data	
or who never visited an ophthalmologist/pediatrician were excluded.
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The primary outcome of this study was the presence of ocular abnormalities in a NS 
population and ophthalmological, pediatric, and genetic data were used. The ocular 
outcomes were linked to the genotypes. In the patients without a known mutation, there 
were either no genetic analyses done or (until now) no mutations identified after testing 
(a selection of) the NS genes. Since NS is a clinical diagnosis, and in 15–20% of the patients 
no causative mutation is known, we included all patients in our study. We included all 
registered ocular abnormalities in the categories vision and refraction, external ocular 
features, ocular alignment and motility, anterior ocular segment, and posterior ocular 
segment. No statistical analyses were used and the results were descriptive.
Results
There were 128 patients who gave permission for the use of their data. In 14 patients, 
no ophthalmological data were available and 9 of 128 patients (7%) were excluded 
because they never visited an ophthalmologist. A total of 105 patients were included 
and	68	of	them	were	younger	than	18 years	old.	The	median	age	of	the	cohort	was	
12 years,	with	a	range	between	1	and	60 years.	Genetic	examinations	showed	a	
causative mutation for NS in 78 patients. The ocular features and gene mutations of 
the	105	NS	patients	are	shown	in	Table 1.	Seven	patients	were	visually	impaired,	
defined as binocular best-corrected visual acuity (BCVA) lower than 0.3, mainly 
attributable to binocular optic nerve abnormalities and manifest nystagmus These 
patients	 had	 a	mutation	 in	 the RAF1gene	 (1	 patient),  SHOC2  gene	 (2	 patients),	
or KRAS gene	(2	patients);	in	1	patient,	no	mutation	was	identified	after	genetic	testing	
and another patient had no genetic analysis. These 7 patients are shown 
comprehensively	 in	Table  	2.	Amblyopia,	defined	as	 visual	 loss	 caused	by	visual	
deprivation (e.g., by strabismus, refractive errors, cataract, or ptosis) in childhood, was 
reported in 28 patients.
Refractive errors, defined as spherical equivalent of ametropia (SEA) of one diopter or 
more, showed myopia (25 patients), hyperopia (39 patients), and astigmatism (35 
patients). High refractive errors, defined as 5 diopters or more, were found for myopia 
in 5 patients, for hyperopia in 2 patients, and for astigmatism in 3 patients, mainly 
associated	with	a	causative PTPN11 mutation.
In 3 patients with a delay in first presentation to an ophthalmologist, ocular abnormalities 
were found. All 3 of them were diagnosed with Noonan syndrome early in childhood. 
They	were	referred	to	an	ophthalmologist	for	the	first	time	at	the	ages	of	17	to	20 years.	
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One of them was diagnosed with visual impairment due to congenital optic nerve 
hypoplasia and the other 2 were diagnosed with high corneal astigmatism resulting in 
keratoconus. In retrospect, visual complaints were noticed earlier in childhood.
External ocular features were frequently found without ophthalmological examination, 
mostly described by pediatricians and clinical geneticists. The findings included 
hypertelorism (63 patients), ptosis (55 patients), and downslanting palpebral fissures 
(39 patients). Other ophthalmological abnormalities included strabismus (40 patients) 
and nystagmus (16 patients). Anterior segment abnormalities included keratoconus 
(4 patients), different types and densities of cataract (3 patients), and posterior 
embryotoxon (2 patients). The posterior ocular segment showed abnormalities of the 
optic nerve head (ONH), including ONH excavation (8 patients), ONH coloboma (1 
patient), ONH hypoplasia (1 patient), and ANH paleness (8 patients) diagnosed as optic 
nerve atrophy in 5 of them.
In	50	patients,	a PTPN11 mutation	was	found	with	genetic	testing.	These	patients	were	
diagnosed with ocular manifestations in the different categories including refractive 
errors, external ocular features, ocular alignment and motility, and abnormalities in 
the anterior and posterior ocular segment. No visual impairment was found in the 
patients	with	a PTPN11 mutation.	In	the	NS	patients	due	to	a SOS1 mutation,	the	most	
frequent ocular findings were hypertelorism and ptosis. We also found prominent 
corneal	nerves.	In	the	group	with	NS	due	to	a RAF1 mutation,	we	found	1	patient	with	
a unilateral exudative retinopathy (Coats disease).
Discussion
In 2016, we published our prospective study of ocular manifestations in 25 Noonan 
syndrome patients (20). The present retrospective cohort shows a larger group, with 
more heterogeneity in the patients and more information on the causative molecular 
findings. This is a retrospective cohort, and therefore we have missing data and there 
might be a response bias. Nevertheless, it is important to show a larger group of 
Noonan syndrome patients including their genetic results, and we hypothesized that 
we could confirm the ocular findings from our prospective cohort.
Visual	impairment	(binocular	BCVA	< 0.3)	was	seen	in	7	patients.	The	cause	of	the	visual	
impairment is probably a developmental disorder of the optic nerves, presenting with 
optic nerve atrophy and optic nerve hypoplasia, associated with nystagmus and 
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Table 1. Ocular features of mutation-positive and mutation-negative patients with Noonan syndrome
(retrospective study; n = 105)
To
ta
l
PT
PN
11
SO
S1
RA
F1
SH
O
C2
M
AP
2K
2
KR
AS
A2
M
L
N
o 
m
ut
at
io
n
 n=105 n=50 n=10 n=7 n=5 n=1 n=4 n=1 n=27
Vision and refraction          
   Visually impaired (both eyes BCVA <0.3) 7 0 0 1 2 0 2 0 2
   Amblyopia (including in history) 28 12 2 3 0 1 2 0 8
   Myopia (SEA ≥ 1D) 25 10 4 2 2 0 2 1 4
         High myopia (≥ 5D) 5 3 0 0 0 0 1 0 1
   Hyperopia (SEA ≥ 1D) 39 23 1 1 2 1 2 0 9
         High hyperopia (≥ 5D) 2 1 0 0 0 0 0 0 1
   Astigmatism (≥ 1D) 35 21 1 3 0 1 1 0 8
         High astigmatism (≥ 5D) 3 2 0 0 0 0 0 0 1
External ocular features
   Hypertelorism 63 30 8 6 2 1 1 1 14
   Ptosis 55 21 8 5 1 1 2 1 16
   Epicanthic folds 32 13 3 2 1 1 1 0 11
   Downslanting palpebral fissures 39 18 5 5 1 1 0 0 9
   Upslanting palpebral fissures 2 1 0 0 0 0 0 0 1
   Proptosis / pseudo-proptosis 8 3 1 1 1 0 0 0 2
Strabismus and ocular motility
   Strabismus 40 17 0 3 4 1 4 0 11
   Limited ocular motility 9 2 0 2 2 1 0 0 2
   Nystagmus 16 5 1 3 2 0 3 0 2
Anterior ocular segment
   Keratoconus 4 2 0 0 0 0 0 0 2
   Prominent corneal nerves 2 0 1 0 0 0 0 0 1
   Corneal opacities 1 0 0 0 0 0 0 1 0
   Posterior embryotoxon 2 1 0 1 0 0 0 0 0
   Iris coloboma 1 1 0 0 0 0 0 0 0
   Cataract 3 1 1 1 0 0 0 0 0
Posterior ocular segment
   Optic nerve head abnormalities 10 5 1 0 1 0 0 1 2
         Excavation (C/D ratio ≥0.5) 8 4 1 0 1 0 0 1 1
         Coloboma 1 1 0 0 0 0 0 0 0
         Hypoplasia 1 0 0 0 0 0 0 0 1
   Optic nerve head paleness 8 2 0 2 1 0 1 0 2
         Optic atrophy 5 1 0 1 1 0 1 0 1
   Retinopathy 1 0 0 1 0 0 0 0 0
BCVA = best-corrected visual acuity; C/D ratio = cup to optic disc ratio; SEA = spherical equivalent of ametropia.
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strabismus. In the prospective study, we had 1 visually impaired patient (20). This 
patient	had	NS	due	to	a BRAF mutation.	In	this	cohort,	we	show	visually	impaired	
patients	with	a RAF1, SHOC2,	or KRAS mutation.	It	is	remarkable	that	in	5	patients	with	
NS	(with	loose	anagen	hair)	due	to	a SHOC2 mutation,	2	patients	are	visually	impaired.	
In the 4 patients with a KRAS mutation, also 2 patients are visually impaired. The cohort 
is too small for genotype-phenotype correlations but it shows that visual impairment 
is	found	in	patients	with	NS	due	to	a SHOC2, KRAS,	and RAF1 mutation.	In	the	50 PTPN11-
positive patients, no visual impairment is found. In 2 patients with NS due to 
a PTPN11mutation, keratoconus is found and the patient with iris coloboma also has 
a PTPN11 mutation.	Keratoconus	in	NS	is	described	in	literature	in	two	case	reports	
(2,7), iris coloboma is described two times (3,6) and cataract is also described in a few 
patients with NS (5,8).
The most frequent external features, are in accordance with the NS cohorts described 
in literature (1,8,10,12,20), including hypertelorism, ptosis, strabismus, downslanting 
palpebral fissures, and epicanthic folds. The external features are important for the 
clinical diagnosis of NS regarding facial characteristics. These external features/ 
periorbital findings are mostly diagnosed by pediatricians and clinical geneticists.
Although it is strongly recommended to do a comprehensive ocular examination in all 
NS patients, still 9 patients never went to an ophthalmologist. In 3 other patients with 
ocular anomalies and reduced vision, there was a delay of many years before they 
were referred to an ophthalmologist. In the international NS guidelines (9,13,15), 
referral for an ophthalmological examination after diagnosing NS is recommended for 
all patients. Examination by an orthoptist and ophthalmologist is also recommended 
for patients with a suspicion of NS. Repeat the ophthalmological examination in 
children	every	2 years	or	as	advised	by	the	ophthalmologist	based	on	the	pathology	
and the expertise of the ophthalmologist and orthoptist. The high prevalence of 
ophthalmological anomalies in NS including amblyogenic factors (ptosis, strabismus, 
astigmatism) makes an early ophthalmological examination necessary (20). For a 
successful treatment of amblyopia, it should be diagnosed in time. Some ocular 
abnormalities in NS patients can occur or increase later in life, for example the 
keratoconus as described above. The guidelines are published in 2010 and 2013, and 
that might be an explanation why older NS patients were not referred to an 
ophthalmological clinic after diagnosing Noonan syndrome. Another reason might be 
that other symptoms, sometimes life threatening, require more attention early in life 
(including cardiac abnormalities and feeding difficulties) and therefore vision and other 
ocular abnormalities do not have priority.
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In conclusion, various ocular abnormalities in childhood, including low visual acuity of 
both eyes leading to visual impairment, are found in a large cohort of patients with 
Noonan syndrome. Permanent visual impairment is mainly caused by binocular optic 
nerve	abnormalities	and	nystagmus	is	found	in	patients	with	a	mutation	in RAF1, SHOC2, 
or KRAS. Timely screening for ocular abnormalities will help to diagnose NS and 
facilitates early treatment of potentially vision threatening abnormalities. For children 
with visual impairment prompt rehabilitation is indispensable for developmental 
purposes. Therefore, an ophthalmologist should examine all patients suspected of, or 
diagnosed with NS.
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Abstract
Objective
This is the first cohort in which hearing impairment and external ear anomalies in 
Noonan syndrome are described extensively.
Methods
Retrospective analysis of the otorhinolaryngological and clinical genetic data from 97 
Noonan Syndrome (NS) patients. Forty-four NS patients were seen by an 
otorhinolaryngologist for the analysis of hearing impairment. In our cohort 80 of the 
97 patients were genetically tested. In 71 of these mutations were found: In 48 patients 
a mutation in PTPN11, in 10 patients in SOS1, in five patients in SHOC2, in five patients 
in RAF1, in one patient in MAP2K2, in one patient in KRAS and in one patient in A2ML1. 
Results
External ear anomalies were reported in 75 NS patients (77%). In 69 patients the ears 
were low-set, 28 patients had posteriorly rotated ears, 14 patients showed protruding 
ears and 18 had thickened helices. Hearing impairment was detected in 34 NS patients. 
Nine patients had sensorineural hearing impairment, two a permanent conductive 
hearing impairment, two other patients had mixed hearing impairment and 20 patients 
had conductive hearing impairment in the past, caused by otitis media with effusion. 
Their temporary conductive hearing impairment resolved between the ages of 2-18 
years. Sensorineural hearing impairment varied between mild high-frequency hearing 
impairment and profound (uni- and bilateral) hearing impairment and was progressive 
in three patients. Four NS patients received cochlear implants for their severe 
sensorineural hearing impairment. The cohort is small for genotype-phenotype 
correlations, but sensorineural hearing impairment, especially the bilateral severe 
hearing impairment, was only seen in patients with a PTPN11 mutation.
Conclusion
NS is characterized by dysmorphic external ear anomalies and both sensorineural and 
conductive hearing impairment. Audiological examinations are recommended in all 
patients with Noonan Syndrome.
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Introduction 
Noonan Syndrome (NS) was first described by Noonan and Ehmke in 1963 (1). A broad 
spectrum of features is seen and multiple abnormalities are characterizing NS. Common 
features include congenital heart anomalies, short stature and facial dysmorphism 
consisting of hypertelorism, short neck, low set ears and downslanting palpebral 
fissures. Other characteristics comprise chest deformity, cryptorchidism, learning 
difficulties and hearing impairment (HI) (2). NS is an autosomal dominant disorder with 
an estimated incidence between 1:1000 and 1:2500 live births (2).
In the literature there are several studies describing NS patients with HI. HI is not 
mentioned as one of the clinical criteria for the diagnosis of NS (3). However, it has 
been linked to NS since 1976 when it was described by Cremers (4). External ear 
anomalies are described as well, mainly as part of facial dysmorphism (2,5). Sharland 
et al. described HI in 40% of the 146 NS patients (6). Qiu et al. also studied data of 
HI in Noonan patients and they found sensorineural hearing impairment (SNHI) in 
50% of the 40 ears without describing further information of the inclusion of NS 
patients (7). 
In 2001 the first gene responsible for NS was discovered and mapped on chromosome 
12q24.1 (8). An activating missense mutation in the PTPN11 gene accounts for 
approximately 50% of the Noonan patients. PTPN11 influences the RAS-MAPK pathway. 
Also other genes of this pathway are involved in NS. KRAS was described in 2006 (9), 
SOS1 in 2007 (10) and also other genes such as BRAF (11), RAF1 (12) and SHOC2 (13) are 
involved in NS. 
In this study, we present data on hearing impairment, external ear anomalies, and 
molecular findings of 97 NS patients. We will compare our results with those in the 
literature and we will give an overview of the genotype-phenotype correlations for HI. 
To the best of our knowledge, this is the first time a large cohort of NS with these 
symptoms is presented with genotype-phenotype correlations.
Methods and patients
We collected retrospective data from 97 NS patients, 49 of them were males and 48 
females. All these patients were seen in our medical center at the human genetic 
department and NS was clinically diagnosed by using the validated criteria of van der 
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Burgt (3,19). In most patients DNA analysis was available. Because most of the patients 
were seen by otorhinolaryngologists, speech and hearing centers and pediatricians 
elsewhere, data were collected on both external ear anomalies and hearing impairment 
after written informed consent. Clinical geneticists, pediatricians or 
otorhinolaryngologists described the external ear anomalies. Forty-four patients were 
seen by an otorhinolaryngologist and in 38 of them audiological tests were performed. 
The other six patients were seen by otorhinolaryngologists with complaints of otitis 
media and other otorhinolaryngological complaints. In this group no audiological tests 
were done because they had no complaints of hearing impairment. We included 97 
patients for the analysis of external ear anomalies and the 44 patients seen by an 
otorhinolaryngologist for the analysis of HI. HI is defined as a high-frequency pure tone 
average (PTA) (average of 1, 2 and 4 kHz) of more than 20dB. In most patients with HI 
analysis, pure-tone audiometry and speech audiometry were performed. In children, 
depending on the age, pure-tone audiometry, visual reinforcement audiometry (VRA), 
Brainstem Evoked Response Audiometry (BERA), Auditory Steady State Responses 
(ASSR), and/or impedance audiometry were used for audiological evaluation. The 
results of the hearing tests were collected retrospectively and were performed in 
different medical centers. In the Netherlands audiological investigations are performed 
in Speech and Hearing Centers and in otorhinolaryngology departments and 44 
patients went to these centers and departments. We assume that in the six patients 
without audiological examinations, there were no clinical signs of HI.
Results
Genotype
NS was clinically diagnosed and DNA analysis was performed in 80 patients. Mutations 
were found in 71 patients. In 48 patients a mutation was found in PTPN11, in 10 patients 
in SOS1, in five patients in RAF1 and in a further five patients in SHOC2. Unusually, we 
found KRAS in one patient, MAP2K2 in another patient and A2ML1 in a further patient. 
In 9 patients DNA analysis was performed and no mutation was found. All of them 
were screened for the PTPN11 gene and six of them were screened for other NS gene 
mutations. In our cohort of 97 patients, in 71 (73%) a mutation in one of the NS-genes 
confirmed the diagnosis of NS. The exact genotypes and the number of patients with 
HI are summarized in Table 1. 
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Table 1. Genotype and hearing impairment in 71 patients
Gene Nucleotide change Amino acid change N SNHI MHI PCHI THI
PTPN11 c.5C>T p.Thr2Ile 1
c.124A>G P.Thr42Ala 3 2
c.179 G>C p.Gly60Asp 1 1
c.181G>A p.Asp61Asn 3 1 2
c.181A>G p.Gln79Arg 1
c.182A>G p.Asp61Gly 2 1
c.184T>G p.Tyr62Asp 1
c.186A>G p.Tyr63Cys 1 1
c.188A>G p.Tyr63Cys 2
c.205G>C p.Glu69Gly 1
c.228G>T p.Glu76Cys 1
c.236A>G p.Gln79Arg 4 1
c.317A>C p.Asp106Ala 1
c.417G>C p.Glu139Asp 1 1
c.794G>A p.Arg265Glu 3 1 1
c. 854T>C p.Phe285Ser 1
c.922A>G p.Asn308Asp 12 2 2
c.923A>G p.Asn308Ser 1 1
c.1472C>T p.Pro491Leu 1
c.1504T>A p.Ser502Thr 1 1
c.1507G>A p.Gly503Arg 1
c.1508G>A p.Gly503Glu 1
c.1510A>G p.Met504Val 4 1
SOS1 c.286G>T p.Trp729Leu 1 1
c.508A>G p.Lys170Glu 1 1
c.742C>T p.Arg248Cys 1 1
c.806T>C p.Met269Thr 1
c.806T>G p.Met269Arg 1
c.1656G>C p.Arg552Ser 1
c.2104T>C p.Tyr702His 1
c.2536G>A p.Glu846Lys 1 1
c.3134C>G p.Pro1045Arg 2
RAF1 c.770C>T p.Ser257Leu 1 1
c.782C>G p.Pro261Arg 1 1
c.1457A>G p.Asp486Gly 2
c.1837C>G p.Leu613Val 1
SHOC2 c.4A>G p.Ser2Gly 5 3
KRAS c.40G>A p.Val14Ile 1 1
MAP2K2 c.401A>G p.Tyr134Cys 1 1
A2ML1 c.4061+1G>A 1
SNHI = sensorineural hearing impairment, MHI = mixed hearing impairment, PCHI = permanent conductive hearing impairment, 
THI = temporary hearing impairment.
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External ear anomalies
Information of the external ear anomalies was obtained from retrospective descriptions 
during visits to the clinical genetics, otorhinolaryngology and pediatric departments. 
External ear anomalies were described in 75 patients out of the total cohort of 97 
patients (77%). These are summarized in Table 2. Low-set ears are the most frequent 
external anomaly, described in 69 patients (71%), followed by posteriorly rotated ears 
in 28 patients (29%), thickened helices in 18 patients (19%), protruding ears in 14 
patients (14%) and dysplastic ears in 4 patients (4%). In 22 patients no external ear 
anomalies were described. 
Hearing impairment
In total 44 patients had visited an otorhinolaryngology department (Table 3). SNHI was 
found in nine patients (20%, age 0-47 years). Four of the nine patients had severe 
congenital HI and in three patients progression of the HI was seen (Table 4). HI and 
mutation analysis of the patients with both SNHI and mixed HI (MHI) is shown in Table 
4. Permanent conductive hearing impairment was measured in two patients with a 
PTPN11 mutation (age 11 and 17). They both had tympanic membrane perforation. It 
was noted that after tympanoplasty their conductive HI persisted. MHI was measured 
in two patients (age 17 and 25), one with a PTPN11 mutation and one without a known 
mutation. In this last patient without a mutation, DNA analysis for PTPN11, SOS1, RAF1, 
KRAS, BRAF and MAP2K2 was performed. Both of these patients had multiple OME 
infections in their medical history. The mutation analysis for 20 patients with temporary 
HI due to otitis media (resolved between age 2-47 years), are shown in Table 1. In total 
33 patients with hearing impairment were found (34% of the total cohort). Four patients 
with severe congenital SNHI received cochlear implants (CI) with good results. The 
audiological results of the non-congenital SNHI are shown in Figure 1.
Table 2. External anomalies in cohort of 97 patients
External ear anomalies Number of 
patients 
PTPN11 
(n=48)
SOS1 
(n=10)
RAF1 
(n=5)
SHOC2 
(n=5)
KRAS 
(n=1)
MAP2K2 
(n=1)
A2ML1 
(n=1)
Low set ears 69 (71%) 34 8 4 4 0 1 0
Posteriorly rotated ears 28 (28%) 11 6 2 3 0 0 0
Thickened helices 18 (18%) 7 1 1 3 0 0 0
Protruding ears 14 (14%) 8 1 1 0 0 0 0
Dysplastic ears 4 (4%) 3 0 0 0 0 0 0
Total external 
ear anomalies
75 (77%) 39
81%
8
80%
4
80%
4
80%
0
0%
1
100%
0
0%
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Discussion
Hearing impairment compared with literature
In 1992 a NS patient with unilateral conductive hearing impairment was reported (5). 
In the same year a large NS cohort was presented in which the audiological results of 
146 patients were described (6).  Hearing impairment was found in 58 patients, mostly 
due to serous otitis media. Of these 146 patients, 5 patients (3%) had sensorineural 
HI.  Another large NS cohort of 151 patients reported hearing impairment in 38% and 
again most of the cases were associated with otitis media (14). No further specifications 
about the hearing impairment were given. Our results are in accordance with these 
Table 3. Hearing impairment
Hearing impairment Number of patients (N 
= 44 out of 97)
Range of age Patients with mutations
Sensorineural hearing impairment 9 (20%) 0 - 47 years 8
Permanent conductive hearing 
impairment
2 (4%) 11 and 17 years 2
Mixed hearing impairment 2 (4%) 17 and 25 years 1
Temporary conductive hearing 
impairment
20 (44%) 0 -18 years 18
Total hearing impairment 33 (75%) 2 - 47 years 29
Table 4. sensorineural hearing impairment and mixed hearing impairment
Patient and 
age of onset
Type of HI Pure Tone Average 
(mean of 1,2 and 4 kHz)
Gene Congenital and 
progression
1)  0 years SNHI 105 dB PTPN11 C, NP
2)  5 years SNHI 28 dB SOS1 CU, P 
3)  43 years SNHI 27 dB PTPN11 NC, NP
4)  47 years SNHI 23 dB SOS1 CU,PU
5)  0 years SNHI 115 dB PTPN11 C, P
6)  7 years SNHI 37 dB RAF1 NC, P
7)  5 years SNHI 92 dB Unknown C, NP
8)  0 years SNHI 90 dB PTPN11 C, NP
9)  0 years SNHI 125 dB PTPN11 C, NP
10) 17 years MHI 45 dB PTPN11 CU, PU
11) 25 years MHI 62 dB Unknown CU, PU
SNHI = sensorineural hearing impairment, MHI = mixed hearing impairment, C = congenital, NC = non congenital, P = 
progressive, NP = not progressive, CU = congenital unclear, PU = progressive unclear.
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percentages. In our total cohort of 97 patients, we found a HI in 34%. A few patients 
with SNHI in NS have been described before in literature: One patient, who had a 
normal hearing level in childhood, the SNHI started at the age of 27. This patient had 
the benefit of hearing amplification (15). This SNHI was possibly due to endolymphatic 
hydrops with central vestibular abnormalities. Another study performed hearing tests 
in 20 patients, 40 ears (7). Pure tone audiometric findings between 250 – 8000 Hz, 
showed HI in 20% of the ears in low frequency range (250-2000 Hz) and in 50% in the 
high frequency range (3000-8000 Hz). 
In general, most Noonan patients with HI have a conductive type of HI that is due to 
otitis media with effusion. But also MHI and SNHI are found. Underlying anomalies 
causing HI are occasionally described. Miura et al. have discussed the results of 
histopathological examinations of the temporal bones in three patients with NS (16). 
Figure 1. Audiological results of patients from Table 4 with non-congenital sensorineural hearing 
impairment.
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Unfortunately, in two of these patients audiological tests were not performed. However, 
in the third patient a bilateral HI was found. The inner ear abnormalities found in the 
three cases had much in common. Reduced numbers of spiral ganglion cells were 
found, the endolymphatic sacs and vestibular aqueducts were dislocated and enlarged 
lateral semicircular canals were reported. The combination of these inner ear anomalies 
with conductive HI caused by otitis media may lead to mixed HI (16) and also the chronic 
or multiple otitis media infections may lead to SNHI. In one case a pure conductive HI 
was described with ossicular chain abnormalities during reconstruction, including the 
absence of the long process of the incus (5). We did not perform any histopathological 
examination in our NS patients. 
Recommendations for future studies
In this study we used retrospective data from different clinics and hospitals. Further 
prospective studies about middle and inner ear abnormalities in NS can provide 
supplemental information of HI in NS and can show a more detailed audiological 
examination. In next studies it would be preferable to perform corresponding 
audiological examinations in all patients and to correlate them to genetic analysis.
Genotype-phenotype correlation
Genotype - phenotype correlation of NS and NS related disorders with HI was studied 
once before in literature (17). Among 24 PTPN11 positive patients, 5 had a SNHI. Among 
the other mutation-positive patients (SOS1, RAF1, BRAF, KRAS and SHOC2) no SNHI was 
measured. No information about the hearing test, severity of HI or ages was given. In 
this cohort we showed nine patients with SNHI, five PTPN11, two SOS1, one RAF1 
mutation and in one patient no mutation was found. Five out of 48 PTPN11 positive 
patients were found to have SNHI. In our study the PTPN11 gene mutation was found 
in all four of the patients with severe bilateral congenital SNHI. They all received CI with 
good results.  Interestingly, the two Noonan patients previously mentioned in the 
literature, who received CI, were also both diagnosed with mutations in the PTPN11 
gene (18). These findings suggest a genotype-phenotype correlation between severe 
bilateral congenital SNHI in NS and the PTPN11 mutation. A larger cohort of SNHI in 
NS patients is needed to confirm this finding. 
In our cohort in 73% of the NS patients a mutation was discovered. However, only 80 
of the 97 patients were tested, suggesting a higher percentage of mutations is likely 
to be more representative. External ear anomalies are frequent NS characteristics. Low 
set ears, posteriorly rotated, thickened helices and protruding ears are not specific 
clinical criteria, but we would recommend to include these features to the recognized 
criteria of facial characteristics of NS.
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Conclusion
Congenital HI is a problem in NS patients, but we know that during childhood or 
adulthood hearing impairment may also develop or show progression. In this 
retrospective cohort of 97 patients, only 44 had been visiting an otorhinolaryngologist 
and even fewer patients underwent hearing examinations. This confirms our hypothesis 
that HI in NS is still an underestimated problem. Although HI is not a life threatening 
disease, it is very important for development and speech of any child. Audiological 
examination is recommended in NS patients (19), especially when clinical signs of HI 
are presented. Furthermore, since HI in NS has been found to be progressive in some 
patients, in those patients with known HI, follow up examinations are strongly 
recommended.
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Abstract
Existing literature only reports a few patients with Noonan syndrome (NS) and Noonan 
syndrome with multiple lentigines (NSML) who underwent cochlear implantation (CI). 
The present study describes four NS patients and one NSML patient with a PTPN11 
mutation. They all had severe to profound hearing loss, and they received a CI. The 
age at which the CI surgery occurred ranged from 1 to 13 years old, and the audiological 
results in all five patients improved after the CI. Otological and audiological examinations 
in NS and NSML are important, and for those with severe hearing loss, the CI surgery 
improved the audiological outcome regardless of age.
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Introduction
Germline mutations in the PTPN11 gene can cause Noonan syndrome (NS) and Noonan 
syndrome with multiple lentigines (NSML). These two developmental disorders have 
numerous shared phenotypic features. PTPN11 encodes the non-receptor protein 
tyrosine phosphatase (SHP-2) (1). NS and NSML are genetically related allelic disorders. 
Mutations that cause NS and NSML modify genes encoding proteins that play a role 
in the RAS-MAPK pathway, leading to pathway disorders. The RAS-MARK pathway is 
an important signal transduction pathway, through which extracellular ligands (growth 
factors, cytokines, and hormones) stimulate cell proliferation, differentiation, survival 
and metabolism (2).
NS is an autosomal dominant congenital disorder with an estimated incidence of 1 in 
1000-2500 live births (3,4) The syndrome is named after the pediatric cardiologist Dr. 
Jacqueline Noonan. NS is characterized by typical craniofacial dysmorphic features 
(broad forehead, hypertelorism, down-slanting palpebral fissures, and low set, 
posteriorly rotated ears), short stature, and congenital heart defects, including 
pulmonary stenosis, as the most frequent cardiac abnormality (5,6). The phenotype is 
variable. Before 2001, the diagnosis of NS was only based on phenotypic features. 
Genetic techniques have recently emerged, making it possible to identify the 
responsible mutations in most patients. Nevertheless, NS is a clinical diagnosis in 
approximately 25% of cases. Mutations in different genes can cause NS, including 
PTPN11, SOS1, KRAS, NRAS, RAF1, BRAF, SHOC2, CBL MAP2K1, A2ML1, SOS2 and RIT1 (2,7,8). 
In approximately 50% of the cases, NS is caused by a missense mutation in the PTPN11 
gene on the chromosomal band 12Q24.1 (9-11).
NSML is a rare autosomal dominant congenital disorder with a high penetrance and 
markedly variable expression. Approximately 200 patients have been reported 
worldwide, but the real incidence of NSML has not been assessed (12). NSML was first 
reported by Zeisler and Becker in 1936 in a 24-year-old woman with lentigines 
(increasing in number), pectus carinatum, hypertelorism and prognathism (12). NSML 
was formerly called LEOPARD, as result of the large overlap with NS, and it is currently 
called NS with multiple lentigines (13). In 1969, the acronym LEOPARD (lentigines, ECG 
conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal 
genitalia, retardation of growth, and sensorineural deafness), which comprised the 
major features, was conceived by Dr. R. Gorlin and Dr. M. Blaw (14). The diagnosis of 
NSML is made on clinical grounds based on the major features. NSML is allelic with NS 
and is caused by different missense mutations in the corresponding genes. PTPN11, 
BRAF and RAF1 are known to be associated with NSML (15).
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Sensorineural hearing impairment is a common feature in NSML, which appears in 
15-20% of all cases (16,17). Hearing impairment is also associated with NS. Sharland 
et al. reported that the incidence of hearing impairment in 146 patients with NS by 
1992 was 40%. In 3% of these cases, hearing impairment was sensorineural and in the 
remaining patients it concerned a conductive hearing impairment. A majority of the 
conductive hearing impairment is attributable to otitis media (4).
Recently, van Trier et al. described 34 patients with Noonan syndrome and hearing 
impairment. Nine patients had a sensorineural hearing impairment, two a permanent 
conductive hearing impairment, two other patients had a mixed hearing impairment 
and 20 patients had a conductive hearing impairment in the past caused by otitis media 
with effusion (18). The sensorineural hearing impairment varied between a mild high-
frequency hearing impairment and a profound (uni- and bilateral) hearing impairment 
that was progressive in three patients (18).
Counseling and special care make it possible for a majority of the patients with NS and 
NSML to function normally in adulthood (6). Because hearing is very important for 
development, a cochlear implant (CI) plays a major role in the rehabilitation of patients 
with bilateral severe sensorineural hearing impairment. Limited information is known 
concerning the outcome of cochlear implantation in patients with NS and NSML. 
Therefore, the aim of the present study was to report the outcomes of five children 
with NS or NSML who were using a CI due to a severe to profound hearing loss. 
Patients and methods
This case series describes four NS patients and one NSML patient, all with a mutation 
in PTPN1 and a severe to profound hearing loss, using a CI. The data for this study were 
gathered retrospectively. The clinical characteristics of all patients are described. The 
audiological data used concerned the outcome of the neonatal hearing screening (with 
Oto Acoustic Emissions) and the objective hearing threshold data obtained by Brainstem 
Evoked Response Audiometry (BERA) or Auditory Steady State Response (ASSR). 
Additionally, we used sound field audiometry (VRA; Visual Reinforcement Audiometry) 
and pure tone audiometry to evaluate the hearing loss pre- and post-cochlear 
implantation. Post-implantation speech perception was assessed using the child-
friendly lists of the NVA test, a standardized Dutch monosyllable test (Dutch consonant-
vowel-consonant [CVC] list, Bosman 1992). Speech perception score was expressed as 
the percentage of correct repeated phonemes. In all of the experiments, the speech 
was presented at a 65 dB Sound Pressure Level (SPL). The mean hearing loss, referred 
to as pure tone average (PTA), was the average hearing threshold at 1, 2 and 4 kHz as 
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a indicator of the degree of speech perception (19,20). To describe the age of the 
patients, the year, month or number of weeks were used. 
Case presentations
Case report 1- NS 
A boy, son of immigrants, was born full term with a birth weight of 3840 grams. The 
parents were non-consanguineous. The clinical examination showed down-slanting 
palpebral fissures, a dysmorphic face and a systolic heart murmur. Echocardiography 
showed a patent foramen ovale. Because of excessive weight loss and neonatal feeding 
problems in the first weeks a genetic analysis was done. At the age of three weeks, the 
neonatal hearing screening was negative. A severe congenital hearing loss was 
confirmed by BERA, which showed no responses at 90 dBnHL. Hearing aids were fitted. 
The diagnosis of Noonan was confirmed with the missense mutation c.1510A>G in 
PTNP11, and a single heterozygous mutation was found in GJB2. Magnetic Resonance 
Imaging (MRI) of the head showed no inner ear abnormalities. However, dorsal bilateral 
cysts in the corpus callosum of 1 mm at the right side and 6 mm at the left were found. 
Electronystagmography showed vestibular hyporeflexia. At the age of 9 months, an 
ASSR was performed and showed a PTA of 90 dB HL at the right ear (Figure 1a) and of 
75 dB HL at the left ear. The best hearing result, determined with VRA, using hearing 
aids showed a PTA of 53 dB HL at the right ear (Figure 1b) and 43 dB HL at the left ear. 
Due to poor auditory development, it was decided that a cochlear implantation was 
needed. At the age of 1;1 he received a Nucleus Freedom CI (Cochlear) at the right side. 
The electrode array was fully inserted. The operation was associated with more than 
the usual diffuse hemorrhage. Seven months after the cochlear implantation, a sound 
field PTA of the right ear with the CI showed 35 dB HL, which remained stable over 
time (Figure 1c). Three years after implantation, a phoneme score of 63% was measured. 
Because of a diagnosed mild intellectual disability and because rehabilitation occurred 
in an environment where sign languages was used, the progress in spoken language 
development remained slow. 
Case report 2- NS 
A full term boy was born with a birth weight of 3660 grams after an antenatal 
polyhydramnion of an unknown origin. The parents were non-consanguineous. The 
father had ichthyosis and epileptic attacks, but no other abnormalities were found in 
the family history. A clinical examination showed erythroderma, mild tachypnea, and 
mild dysmorphic features, including hypertelorism, retrognathia, dysplastic and low-set 
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Figure 1. Audiological results of patient 1
Right ear; Figure 1a presents the pre-implantation 
thresholds without hearing aids, Figure 1b presents the 
pre-implantation thresholds with hearing aids and Figure 
1c presents the post-implantation thresholds with CI. The 
legend in the figure comprises the age at testing and the 
method used; ASSR = Auditory Steady State Response, 
VRA = Visual Reinforcement Audiometry, FU = follow-up 
sound field testing with CI and m = months.
Figure 2. Audiological results of patient 2
Right ear; Figure 2a presents the pre-implantation 
thresholds without hearing aids, Figure 2b presents the 
pre-implantation thresholds with hearing aids and Figure 
2c presents the post-implantation thresholds with CI. The 
legend in the figure comprises the age at testing and the 
method used; ASSR = Auditory Steady State Response, 
VRA = Visual Reinforcement Audiometry, FU = follow-up 
sound field testing with CI and m = months.
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ears, sandal gap deformity and skinfold thickness of the neck. By auscultation, a systolic 
heart murmur was found. Additionally, echocardiography revealed a left ventricular 
dilatation with ventricular wall hypertrophy. The patient had diffuse xerosis cutis with 
lamellar scaling skin. This was diagnosed as x-linked ichthyosis by a Xp22.31 deletion. 
Psychomotor retardation, intellectual disability and short stature were diagnosed. After 
a negative neonatal hearing screening test, a BERA was performed at 8 weeks of age. 
No responses were detected at a stimulus of 90 dBnHL, which confirmed a congenital 
severe hearing impairment. With electronystagmography, an asymmetric vestibular 
areflexia at the right side was found. An MRI showed no cerebral or inner ear 
abnormalities. A mutation (c. 124A>G) in the PTPN11 gene was found, which confirmed 
the diagnose of NS. Hearing aids were fitted, but auditory development was limited. 
An ASSR, performed before the implantation, showed a PTA at the right ear (Figure 2a) 
of 105 dB HL and 93 dB HL at the left ear. Pre-implantation, a VRA audiogram showed 
thresholds of approximately 80 dB HL, with hearing aids (Figure 2b). Frequent otitis 
media was observed. At the age of 1;8, the patient received a Nucleus Freedom CI 
(Cochlear) in the right side. During the operation, an abnormal procedure was 
necessary. The chorda tympani had an abnormal trajectory, being more posterior. The 
chorda tympani was mobilized from its canal to make an appropriate opening. However, 
a cochleostomy through a posterior tympanotomy opening was still impossible, and 
the insertion was therefore conducted after removing the back of the bony ear canal 
wall, which was reconstructed with cartilage. The electrode array was fully inserted. 
Twelve months after the implantation, a PTA of 43 dB HL at the right ear was found 
(Figure 2c). Thirty-seven months post-implantation, the PTA had improved to 28 dB HL, 
and that value was stable over time. Seven years after implantation, a phoneme score 
of 90% was measured. Because of an intellectual disability, language comprehension 
improved, but at a slower pace than normal. 
Case report 3- NS 
This case comprises a girl born after 36 weeks of gestation. A clinical examination showed 
mild dysmorphic features (curly hair, ptosis, epicanthus, cup ear at the right side and, 
left dysplastic helix). No abnormalities were found by family history. By auscultation, a 
systolic murmur was found. Echocardiography showed a valvular pulmonary stenosis 
with good left ventricle functions. She had a growth retardation of more than 2 SD below 
the mean. After a negative neonatal hearing screening, a BERA was performed, which 
showed no reproducible response up to 90 dBnHL. The child had multiple ear infections. 
The motor development was normal; however, a mental development delay was present. 
At the age of 3;5, the diagnosis of Noonan syndrome was confirmed with a c.922A>G 
mutation in the PTPN11 gene. No inner ear abnormalities were found by Computed 
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Tomography (CT). A vestibular examination revealed areflexia on both sides. Initially, 
hearing aids were used in combination with sign language, but the result was poor, and 
it was thus decided to implant the child with a CI. Pre-implantation, audiometry showed 
no reliable responses up to 120 dB HL on either ear (Figure 3a). With the fitted hearing 
aids, sound-field thresholds of approximately 70 dB HL were found (Figure 3b). At the 
age of 3;9, a Nucleus Freedom CI (Cochlear) was implanted in the right side with full 
insertion. In addition to a diffuse hemorrhage, no complication occurred. Two months 
after implantation, sound-field testing was performed and showed a PTA of 45 dB HL 
with the CI. Six years and three months post-implantation, the PTA improved to 28 dB 
HL (Figure 3c), and a phoneme score of 70% was found. The delay in language 
development remained; however, progress was obvious. 
Case report 4- NS 
A girl was born after 36 weeks of gestation with a birth weight of 2250 grams. The 
family history was uneventful. A clinical examination showed low-set ears, severe 
pectus excavatum, short stature, short neck and a heart murmur. An atrioventricular 
septal defect, an atrial septal defect type II and a severe left ventricular outflow 
obstruction based on a mitral valve disorder were found. Hemostasis disorders were 
detected with a mildly decreased von Willenbrand factor and coagulation factors (VII, 
VIII, IX, XI). Because this is insufficient for normal coagulation, a peri-operative treatment 
with desmopressin and tranexamic acid were required. Before the age of one year she 
underwent a surgical correction for these congenital heart abnormalities. Clinically, 
she was diagnosed with NS, and a DNA analysis confirmed a missense mutation 
c.124A>G in PTPN11. Because of the heart problems, the hearing impairment was not 
noticed. A short stature of 2 SD below the mean was detected. The patient had a mild 
intellectual disability. However, motor development was normal. At the age of 1;4, VRA 
showed a PTA of 88 dB HL (Figure 4a). At the age of 3;0, she received hearing aids, 
which improved the PTA to 50 dB HL (Figure 4b). Using tone audiometry, a PTA of 102 
dB HL was measured in both ears at the age of 3;7. An otitis media was observed 
frequently. The hearing loss progressed slowly over the years, which resulted in a PTA 
of 113 dB HL in the right ear (Figure 4a) and 115 dB HL in the left ear, which were 
measured at the age of 13;5. Initially, a phoneme score of 50% with hearing aids was 
measured, and this score dropped significantly when it was measured at the age of 
13;5. Therefore, she became eligible for a cochlear implantation. The pre-operative 
testing with hearing aids showed a phoneme score of 25% in the right ear and 44% in 
the left ear. No abnormalities were found with a CT scan and vestibular testing. At the 
age of 13;10, she received a Nucleus 5.12 (Cochlear) in the right side. The electrode 
array was fully inserted. Seven months after the implantation, a PTA of 22 dB HL (Figure 
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Figure 3. Audiological results of patient 
Right ear; Figure 3a presents the pre-implantation 
thresholds without hearing aids, Figure 3b presents the 
pre-implantation thresholds with hearing aids and Figure 
3c presents the post-implantation thresholds with CI. The 
legend in the figure comprises the age at testing and the 
method used; ASSR = Auditory Steady State Response, 
VRA = Visual Reinforcement Audiometry, FU = follow-up 
sound field testing with CI, m = months and y = year.
Figure 4. Audiological results of patient 4
Right ear; Figure 4a presents the pre-implantation 
thresholds without hearing aids, Figure 4b presents the 
pre-implantation thresholds with hearing aids and Figure 
4c presents the post-implantation thresholds with CI. The 
legend in the figure comprises the age at testing and the 
method used; ASSR = Auditory Steady State Response, 
VRA = Visual Reinforcement Audiometry, FU = follow-up 
sound field testing with CI and m = months.
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4c) and a phoneme score of 87% were measured. Because of the mild intellectual 
disability and the long-standing severe hearing loss, language development remained 
behind normal levels. 
Case report 5- NSML 
A girl was born at 39 weeks of gestation with a birth weight of 3985 grams. No 
abnormalities were found in the family history. By the clinical examination, dysmorphic 
features, frontal bossing and mild ptosis were observed. By auscultation, a systolic 
murmur was found. Echocardiography showed a hypertrophic cardiomyopathy without 
obstruction and good contractions. A mild peripheral pulmonary stenosis was detected. 
After a negative neonatal hearing screening, a BERA was performed at the age of 19 
days, which showed responses at 70 dBnHL in the right ear and 60 dBnHL in the left 
ear. A second BERA, performed one month later, showed no reproducible responses 
at 90 dBnHL. Hearing aids were fitted. At the age of 0;7, except for bilateral opacification 
of the mastoid, no temporal bone abnormalities were found by MRI. However, there 
were minimally enlarged ventricles, and the myelinization of the frontal lobe was 
slightly behind. These findings can be explained by the age at the time of the MRI. 
However, a motor retardation was present. The mental development was normal.
A short stature of 2 SD was detected. No vestibular abnormalities were found with 
nystagmography. A VRA was performed at the age of 0;11 and showed a hearing loss 
of 97 dB in the left ear and 93 dB in the right ear (Figure 5a). With bilateral hearing aids, 
thresholds of approximately 40 dB HL were found (Figure 5b). Frequently, an otitis 
media was observed. Despite aided thresholds of 40 dB HL, the auditory and language 
development remained at a low level, and at the age of 1;4, she received a Nucleus 
5.12 (Cochlear) CI in the right side. The electrode array was fully inserted and no 
complication occurred. A second Nucleus 5.12 (Cochlear) CI was implanted in the left 
side at the age of 1;10. Again, the electrode array was fully inserted. Before the second 
implantation, a PTA was measured of more than 110 dB HL at the left ear, and with 
the hearing aid, a PTA of 58 dB HL was found (Figure 5d and Figure 5e). At the age of 
2;7, the hearing thresholds were measured with the CI, and the PTA in the right ear 
was 32 dB HL and in the left ear was 25 dB HL (Figure 5c and Figure 5f). The phoneme 
score in the right ear was 85% and in the left ear was 60%. Between the age of 3 to 4 
years, the phoneme scores improved to 90% and 89%, respectively. After implantation, 
language comprehension improved and became age appropriate. At the age of 4, 
multiple skin disorders were detected, which led to NSML. On the left side of the 
buttocks, a large cafe au lait spot was presented. At her face and thorax, multiple 
lentigines were found. A genetic analysis confirmed NSML with a missense mutation 
in PTPN11, c.836A>G. 
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Discussion
Patients compared with the literature
After cochlear implantation, audiological results, including speech recognition, 
increased in all of our patients with a mutation in PTPN11, despite an implantation at 
a relatively late age. In all of the patients there was language development; however, 
in the majority, due to intellectual disability and severe hearing loss during the first 
years of life, it was not age appropriate, except for the last case (3.5).  
Figure 5. Audiological results of patient 5
Right ear; Figure 5a presents the pre-implantation 
thresholds without hearing aids, Figure 5b presents the pre-
implantation thresholds with hearing aids and Figure 5c 
presents the post-implantation thresholds with CI.  
Left ear; Figure 5d presents the pre-implantation 
thresholds without hearing aids, Figure 5e presents the 
pre-implantation thresholds with hearing aids and Figure 
5f presents the post-implantation thresholds with CI. The 
legend in the figure comprises the age at testing and the 
method used; VRA stands = Visual Reinforcement 
Audiometry, FU = follow-up sound field testing with CI and 
m = months.
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Despite the limited number of implanted patients described in this case series, it is the 
largest number of implanted patients with a mutation in PTPN11 described in the 
literature. In 2009, Scheiber et al. reported two patients with NS. They received their 
CI at the ages of 2 and 4 years. These patients had missense mutations c.922A>G and 
c. 853T>C, both in the PTPN11 gene. Both of the patients presented with an absent 
development of speech and language. After implantation, the two-year-old child had 
a PTA of 25 dB HL and the four year old child was at 43 dB HL. Speech recognition 
scores were not presented (21). The four NS patients presented in our case series show 
comparable or better sound-field thresholds with CI.
In 2013, Ho-Suk Chu et al. described a girl with NSML that was implanted at the age 
of 5. The patient had a mutation in PTPN11, which was a missense mutation c. 1381G>A. 
One year after implantation, the patient was able to respond to loud sounds. However, 
she was not able to deliver meaningful communication. This is in contrast with the 
results in the current study. However, the minimal benefit described by Ho-Suk Chu 
et al. in 2013 was possibly caused by concomitantly acquired cerebral palsy, which 
might have limited her ability to develop language (22). 
NS and NSML are allelic disorders that are caused by a different heterozygous missense 
mutation in the same gene. Because of the underling RAS-MARK pathway dysregulation, 
NS and NSML have numerous overlapping phenotypical features. However, both 
syndromes are heterogeneous. All of the patients described until now with NS and 
NSML using a CI had a mutation in the PTPN11 gene. In addition, out of all of the 
patients diagnosed with NS and NSML in our clinic, only patients with a mutation in 
the PTPN11 gene had severe to profound hearing loss and thus received a CI (Table 1). 
Clinical recommendations and future studies
Not much is known about the phenotype-genotype correlation of hearing impairment 
in NS and NSML patients. Studies that show the pattern of hearing impairment over 
time would be useful. All of the patients presented in this study had a congenital onset 
of hearing impairment. One of the patients with NS seemed to have had a progression 
of hearing impairment over time. However, frequent otitis media might have played a 
role. The patient with NSML showed a severe progression in the first year of her life. 
Sensorineural hearing impairment is a feature that appears frequently in patients with 
NS and NSML. Therefore, otological and audiological examinations should be performed 
regularly. 
There are some important phenotypic features to take into account in the work-up to 
cochlear implantation, including temporal bone abnormalities, bleeding disorders, and 
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a variable degree of neurocognitive delay. Pre-implantation, the status of the mastoid 
pneumatization and the associated inner ear abnormalities should be evaluated 
carefully because structural anomalies of the inner ear and petrous bone have been 
reported in patients with NS and NSML (23, 24). However, in all our patients, the anatomy 
of the temporal bone was normal. With different surgical techniques, a CI was possible 
in these cases and even with a good outcome. In general, up to 55% of all NS patients 
have a mild to moderate bleeding tendency. Severe hemorrhage occurs in 3% of all 
patients with NS (6). Special care might be required to prevent intra-operative and post-
operative hemorrhage. In the current study, two out of the four NS patients had mild 
hemorrhage during the operation, and one patient had a hemostasis disorder. This is 
important to keep in mind before surgery. In both syndromes, variable cognitive deficits 
are described. Intellectual disability is present in 15-35% of all patients with NS and is 
usually mild (6). Four of our patients had an intellectual disability. However, the degree 
was variable. In 30% of all NSML cases, an intellectual disability is observed (25). This 
was not the case in our NSML patient. Because of the possibility of neurocognitive delay 
due to auditory deprivation, early hearing rehabilitation seems to be even more 
important in cases of such intellectually disabled children with hearing loss. 
Conclusion
Appropriate knowledge of the phenotype-genotype correlations and of the outcome 
of cochlear implantation in genetic hearing impairment is important in the work-up to 
a CI. CI surgery in NS patients might be challenging because of the abnormal anatomy, 
hemorrhage and neurocognitive delay. However, acceptable but variable results are 
presented in these case series.
Table 1. Overview of all NS and NSML patients in the current study and the literature with CI.
Patient Authors Syndrome Gene Nucleotide change Amino acid change
1 Current study NS PTPN11 1510A>G Met504Val
2 Current study NS PTPN11 124A>G Thr42Ala
3 Current study NS PTPN11 922A>G Asn308Aps
4 Current study NS PTPN11 124A>G Thr42Ala
5 Scheiber et al (19) NS PTPN11 922A>G Asn308Asp
6 Scheiber et al (19) NS PTPN11 853T>C Phe285Leu
7 Current study NSML PTPN11 836A>G Tyr279Cys
8 Ho-Suk Chu et al (20) NSML PTPN11 1381G>A Ala461Thr
NS = Noonan Syndrome, NSML = Noonan syndrome with multiple lentigines, CI = cochlear implantation.
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General
Noonan syndrome is characterized by a wide spectrum of features and symptoms. 
Different symptoms and characteristics are studied and described in literature, some 
more frequent than others. Distinctive facial symptoms are described frequently, 
including external ear and external ocular characteristics. Studies for hearing 
impairment and ocular manifestations in Noonan syndrome are found less frequent 
in literature. 
The first gene responsible for Noonan syndrome was found in 2001. Many molecular 
studies are performed since. In approximately 80% of the clinically diagnosed Noonan 
syndrome patients, a germline mutation in one of the known Noonan syndrome genes 
is found. There is a broad phenotypic range and genotype-phenotype studies show 
large variability, also within families. To gain more insight in the intra-familial phenotypic 
expression we studied a large Noonan syndrome family with a new SOS1 mutation.  
The aim of this thesis was to improve the clinical knowledge and recognition of Noonan 
syndrome. We performed new studies to investigate hearing impairment and ocular 
characteristics in Noonan syndrome and we described a large Noonan syndrome family 
due to a new SOS1 mutation to get more insight in genotype-phenotype correlations 
within one family. With better insight in the hearing problems and ocular features 
including visual impairment, healthcare for the Noonan syndrome patients can be 
improved. Furthermore, genotype-phenotype correlations will help in diagnosing 
Noonan syndrome and will improve the healthcare and follow-up throughout their 
lives. 
Genotype, phenotype and correlations
Until 2001 Noonan syndrome was solely diagnosed by clinical characteristics. In 2001 
the PTPN11 gene was the first gene discovered to cause Noonan syndrome (1). As, in 
the moment, only in about three-quarter of the Noonan syndrome patients the 
diagnosis can be confirmed by one of the known germline mutations, Noonan 
syndrome still is a clinical diagnosis. Van der Burgt described a scoring system for the 
clinical diagnosis of Noonan syndrome in 1994, with an update in 2007 (2). The clinical 
diagnosis is preferably confirmed by a mutation in the RAS/MAPK pathway. 
In recent years more studies with genetic testing are performed and genetic testing 
for diagnosing Noonan syndrome is becoming more prominent, also in individuals and 
studies without a clear clinical diagnosis. Due to the high number of genes causing 
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Noonan syndrome and related disorders, standard diagnostic testing of all the NS-
genes using Sanger sequencing is expensive and a relatively long process. Next 
generation sequencing, including whole genome sequencing and targeted next 
generation sequencing, is suggested to be a more accurate and cost-effective 
genotyping. RASopathies have a high genetic and phenotypic heterogeneity. For an 
easier and more accurate way of diagnosing Noonan syndrome, we expect next 
generation sequencing to play a more important role in the nearby future. Molecular 
characterization that will lead to an early diagnosis, also in patients with mild or atypical 
clinical features, will improve the clinical care for Noonan syndrome patients (3). 
Genotype-phenotype correlations in Noonan syndrome have become a more popular 
subject in literature since more causative mutations in different genes have been 
discovered. PTPN11 mutations are found in approximately 50% of the Noonan 
syndrome patients and therefore play an important role in genotype-phenotype 
studies. In Noonan syndrome patients with a PTPN11 mutation, frequently described 
features are short stature, pectus deformities, cardiac abnormalities and facial 
characteristics (4,5). Very typical facial characteristics are described in patients with 
KRAS mutations (6) and intellectual disabilities occur more frequent in patients with 
KRAS mutations (7). Frequent described features in patients with SOS1 mutations are 
cardiac anomalies, facial characteristics and ectodermal abnormalities (8). Overall in 
literature, the broad variety of clinical characteristics (from very mild to typical) in both 
mutation positive and mutation negative Noonan syndrome patients is emphasized. 
Noonan syndrome and related disorders
Noonan syndrome and related disorders are caused by germline mutations in distinct 
genes all leading to dysregulation of components of the RAS-MAPK pathway. They are 
named together as RASopathies and include among others Noonan syndrome with 
multiple lentigines (LEOPARD syndrome in the past), cardiofaciocutaneous syndrome, 
Costello syndrome, and Noonan-like syndrome with loose anagen hair (3). Noonan 
syndrome is characterized by a broad spectrum of features and shares clinical features 
with the related disorders. In Chapter 6 we showed hearing impairment in both 
Noonan syndrome and Noonan syndrome with multiple lentigines, based on different 
PTPN11 gene mutations. 
Monogenic diseases caused by a modification in the DNA sequence of only a single 
gene, are easier to understand and recognize. It becomes more complicated when 
mutations occur in genes that encode proteins that have multiple interactions in large 
protein networks, for example the RAS-MAPK pathway. The fact that the mutated 
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proteins can express in different organs and tissues makes it even more interesting 
(9). Noonan syndrome and other RASopathies have mutations in different core 
components of the RAS-MAPK pathway, but the individual patients show many of the 
same developmental defects, including cardiac anomalies, facial dysmorphology and 
skin abnormalities. Clinical trials for improving the cognitive functioning in children 
with a RASopathy, did not show a significant change. Also other treatments, for example 
MEK inhibitors, did not clearly improved the symptoms in RASopathies (9,10). This all 
confirms the complexity and difficulties of the RASopathies. 
Mutation in SOS1 gene
In Chapter 2 we present a large Noonan syndrome family due to  a SOS1 mutation. 
The phenotype shows a broad spectrum of characteristics, ranging from only few 
suggestive features to typical Noonan syndrome characteristics. The typical 
characteristics were mostly found in the youngest generation of the family. Our study 
confirms large intra-familial variability in clinical characteristics in the same genetically 
confirmed SOS1 mutation. This facial variability might be due to a changing phenotype 
with ages, which is also suggested in the literature (11). Another explanation for the 
variety within one family might be epigenetic mechanisms. In 2015, three family 
members with a SOS1 mutation with phenotypical variation were described. Research 
was conducted on allelic expressions and a different allelic expression of SOS1 in 
healthy individuals was found (12). They hypothesized that epigenetic mechanisms 
might be responsible for the variable clinical expression of SOS1 pathogenic alleles 
(12). Furthermore it is suggested that non-coding regions can be involved in the 
aetiology of diseases (13). 
Ocular manifestations
Ocular abnormalities are described in up to 100% of the Noonan syndrome patients 
(14,15), but few studies have reported comprehensively about the ocular features. 
Complete ophthalmologic examinations for both external and inner ocular 
manifestations are rare. In Chapter 3 we describe the complete ophthalmologic 
examination we performed prospectively in 25 Noonan syndrome patients. External 
ocular abnormalities are an important part of the facial characteristics and include 
hypertelorism, ptosis, epicanthic folds and downward slanting palpebral fissures. Other 
frequently and remarkably found ocular manifestations include refractive errors, 
amblyopia, strabismus and abnormal stereopsis. Abnormalities in the anterior segment 
include prominent corneal nerves and posterior embryotoxon and in the posterior 
segment include optic nerve head excavation. Our prospective observational study 
shows the variety of multiple ocular manifestations in Noonan syndrome. We included 
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one patient with a BRAF mutation and this patient showed the lowest visual acuity with 
optic nerve hypoplasia. Furthermore we found high prevalence of ptosis, including a 
marked asymmetry between the right and the left eye. In conclusion, we found an 
extensive variety of congenital ocular abnormalities in Noonan syndrome patients 
characterized by developmental anomalies of the eyelids and associated with other 
ocular abnormalities in childhood. 
In Chapter 4 we collected data in a large Noonan syndrome cohort and included 
ophthalmologic and genetic data of 105 patients. Besides the incidence of ocular 
manifestations in a retrospective and large cohort, we were also interested if the 
international Noonan syndrome guidelines have been followed (16). We hypothesized 
to confirm the ocular findings from our prospective cohort. We found reduced vision 
in seven patients, five of them had a mutation in RAF1, SHOC2, or KRAS gene. We also 
found high percentages of external ocular manifestations, refractive errors (myopia, 
hyperopia, and astigmatism), amblyopia and strabismus. Less frequent ophthalmic 
manifestations were nystagmus, keratoconus and optic disk excavation. It was 
remarkable to see that, although it is strongly recommended to do a comprehensive 
ocular examination as soon as the patient is diagnosed with Noonan syndrome, nine 
patients never visited an ophthalmologist and in three other patients there was a delay 
of many years before they had their first ocular examination. In the guidelines, referral 
for an ophthalmology assessment is recommended at the point of diagnosis. Further 
management and follow-up should be as deemed appropriate by the ophthalmologist 
(16).
Hearing and ear manifestations
Hearing impairment was linked to Noonan syndrome for the first time in 1976 (17) and 
is described in several Noonan syndrome studies (18,19). External ear anomalies are 
described in Noonan syndrome, mostly as part of facial dysmorphism. In Chapter 5 
we presented data on hearing impairment, external ear anomalies and genetic findings 
in 97 patients. The hearing impairment was divided into four categories: sensorineural 
hearing impairment, mixed hearing impairment, permanent conductive hearing 
impairment, and temporary hearing impairment. Nine patients had sensorineural 
hearing impairment, and four of them had severe congenital hearing impairment. In 
all four patients with severe congenital hearing impairment, a PTPN11 mutation was 
found. They all received cochlear implants with good results. Interestingly, the two 
Noonan syndrome patients previously mentioned in literature who received cochlear 
implants, were both diagnosed with a mutation in the PTPN11 gene (20). Permanent 
conductive hearing impairment and mixed hearing impairment were found in 2 
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patients. Temporary hearing impairment was seen in 20 patients, due to otitis media 
with effusion. Possible underlying anomalies causing hearing impairment in Noonan 
syndrome described in literature are inner ear anomalies, including reduced numbers 
of spiral ganglion cells, dislocated endolymphatic sacs and vestibular aqueducts, and 
enlarged lateral semicircular canals. The combination of inner ear anomalies and 
conductive hearing impairment due to otitis media, may lead to mixed hearing 
impairment. Also chronic and multiple otitis media infections may lead to sensorineural 
hearing impairment. Congenital hearing impairment is a problem in Noonan syndrome, 
but hearing impairment may also show progression during life. 
Sensorineural hearing impairment is found in Noonan syndrome and other RASopathies 
including Noonan syndrome with multiple lentigines. Counseling and special care make 
it possible for the majority of patients with a RASopathy and hearing impairment to 
function normally in adulthood. Cochlear implantations play an important role in 
patients with severe bilateral sensorineural hearing impairment. Therefore we have 
reported the outcome of five children with cochlear implants in Chapter 6. The case 
series describes four patients with Noonan syndrome and one with Noonan syndrome 
with multiple lentigines, all with a mutation in the PTPN11 gene. After cochlear 
implantation, the audiological results, including speech recognition, increased in all 
five patients. However in four of them it was not age appropriate due to severe hearing 
loss in the first years of life an intellectual disability. All the patients in our study, and 
the patients described in literature, are diagnosed with severe to profound hearing 
loss and with a mutation in the PTPN11 gene (21). Sensorineural hearing impairment 
is a feature that occurs on regular base in Noonan syndrome and other RASopathies 
including Noonan syndrome with multiple lentigines and therefore audiological and 
otological examinations should be performed in all patients. 
Future prospects
Currently, we still use clinical features for the diagnosis of Noonan syndrome and other 
RASopathies and we support the clinical diagnosis with genetic testing and confirming 
germline mutations if available. Molecular testing of RASopathies is improving with 
next generation sequencing and new molecular studies are needed to discover more 
causative mutations in the nearby future. 
Furthermore, research is necessary to better understand the RAS/MAPK pathway. By 
better understanding of the mechanisms that drive genotype to phenotype in the 
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RASopathies, treatments might become available. Hopefully at one day we will 
understand the complex signaling pathways and the genes that can control them and 
this will lead to possible therapeutic approaches. 
Creating an international database can be an important first step in discovering new 
genes and genotype-phenotype correlations. Most studies include relatively small 
numbers of patients. When the clinical features and germline mutations of all 
RASopathies will be collected together, more questions can be answered. More 
international collaboration will also lead to better clinical care. A good example is the 
first management guidelines published in 2010 by a European consortium (16). The 
guidelines are translated in Dutch as well and are an important guide in the clinical 
care for Noonan syndrome patients. 
In our clinical studies we found a group of Noonan syndrome patients who never visited 
an ophthalmologist and/or otorhinolaryngologist. The guidelines clearly advise vision 
screening and hearing assessment. Therefore we recommend referring patients with 
(suspicion of) Noonan syndrome to experienced healthcare providers, who work in a 
patient centered multidisciplinary clinic. This will lead to a continuity of care and 
improvement of patient care. It will also offer the opportunity to participate in 
(international) research and will lead in the end to better healthcare for Noonan 
syndrome patients. In the Netherlands a new collaboration will start. The patient 
centered multidisciplinary clinic will work together with the Dutch Noonan syndrome 
foundation. This collaboration should lead to better patient healthcare, new research 
projects, more enrollment in studies, and to an (inter)national anonymous database.
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   107 24-09-18   08:45
CHAPTER 7
108    
References
1. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations 
in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. 
Nature Genetics. 2001;29:465-468.
2. Van der Burgt I. Noonan syndrome. Orphanet Journal of Rare Diseases. 2007;2:4.
3. Lepri FR, Scavelli R, Digilio MC, Gnazzo M, Grotta S, Dentici ML, et al. Diagnosing of Noonan 
syndrome ad related disorders using target next generation sequencing.  B M C 
Med Genet. 2014;15:14.
4. Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, et al. Genotype-phenotype 
correlations in Noonan syndrome. J Pediatr. 2004;144:368-374.
5. Jongmans M, Sistermans EA, Rikken A, Nillesen WM, Tamminga R, Patton M, et al. Genotypic 
and phenotypic characterization of Noonan syndrome: new data and review of the literature. 
Am J Med Genet A. 2005;134A:165-170.
6. Allanson JE, Bohring A, Dorr HG, Dufke A, Gillessen-Kaesbach G, Horn D, et al. The face of 
Noonan syndrome: does phenotype predict genotype. Am J Med Genet A. 2010;152A:1960-
1966.
7. Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, et al. Germline missense 
mutations	 affecting	 KRAS	 isoform	 B	 are	 associated	 with	 a	 severe	 Noonan	 syndrome	
phenotype. American Journal of Human Genetics. 2006;79:129-135.
8. Narumi Y, Aoki Y, Niihori T, Sakurai M, Cavé H, Verloes A, et al. Clinical manifestations in 
patients with SOS1 mutations range from Noonan syndrome to CFC syndrome. J Hum 
Genet. 2008;53:834-841.
9. Keenan SE, Shvartsman SY. Mechanisms and causality in molecular diseases. Hist Philos Life 
Sci. 2017;39:35.
10. Rauen KA. The RASopathies. Annual Review of Genomics and Human Genetics. 2013;14:355-
369.
11. Allanson JE, Hall JG, Hughes HE, Preus M, Witt RD. Noonan syndrome: the changing 
phenotype. American  Journal of Medical Genetics. 1985;21(3):507-14.
12.	 Moncini	S,	Bonati	MT,	Morella	I,	Ferrari	L,	Brambilla	R,	Riva	P.	Differential	allelic	expression	
of SOS1 and hyperexpression of the activating SOS1 c.755C variant in a Noonan syndrome 
family. Eur J Hum Genet. 2015;23:1531-1537.
13.	 Serre	D,	Gurd	S,	Ge	B,	Sladek	R,	Sinnett	D,	Harmsen	E,	et	al.	Differential	allelic	expression	
in the human genome: a robust approach to identify genetic and epigenetic cis-acting 
mechanisms regulating gene expression. PLoS Genet. 2008;4:e100006.
14. Mendez HM, Opitz JM. Noonan syndrome: a review. American Journal of Medical Genetics. 
1985;21:493-506.
15. Lee NB, Kelly L, Sharland M. Ocular manifestations of Noonan syndrome. Eye. 1992;6:328-
334.
16. Group: TNSGD, Kerr B, Van der Burgt I, Biswas S, Clayton-Smith J, Dahlgren J, Gelb, B, et al. 
Noonan Syndrome  Clinical Management Guidelines. University of Manchester: Dyscerne; 
2010.
17. Cremers C. Letter: Hearing loss in Noonan syndrome. Journal of Pediatrics. 1976;88:363.
18. Sharland M, Burch M, McKenna WM, Paton MA. A clinical study of Noonan syndrome. 
Archives of Disease in Childhood. 1992;67:178-183.  
19. Qiu WW, Yin SS, Stucker FJ. Audiologic manifestations of Noonan syndrome. Otolaryngology 
Head and Neck Surgery. 1998;118:319-323.
20. Scheiber C, Hirschfelder A, Grabel S, peters H, Olze H. Bilateral cochlear implantation in 
children with Noonan syndrome. Int J Pediatr Otorhinolaryngol. 2009;73:889-894.
21. Chu HS, Chung HS, Ko MH, Kim HJ, Ki CS, Chung WH, et al. Syndromic hearing loss in 
association with PTPN11-related disorder: the experience of  cochlear implantation in a 
child with LEOPARD syndrome. Clin Exp Otorhinolaryngol. 2013;6:99-102.
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   108 24-09-18   08:45
109
 
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   109 24-09-18   08:45
Nederlandse samenvatting
8
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   110 24-09-18   08:45
Nederlandse samenvatting
8
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   111 24-09-18   08:45
CHAPTER 8
112    
Het Noonan syndroom  is een erfelijke aandoening die wordt gekenmerkt door een 
breed scala aan symptomen. Uiterlijke kenmerken komen vaak voor, zoals 
hypertelorisme (ogen die verder uit elkaar staan) en laagstaande oren die naar achter 
zijn gekanteld. Andere symptomen zijn onder andere hartafwijkingen, groeistoornissen, 
borstkasafwijkingen, verminderde intelligentie en achterblijvende motoriek. Studies 
naar slechthorendheid en oogafwijkingen met daarbij visusstoornissen bij patienten 
met het Noonan syndroom zijn minder vaak beschreven in de literatuur.
Het Noonan syndroom  wordt veroorzaakt door een mutatie (een verandering in een 
gen). Het eerste gen dat verantwoordelijk is voor het Noonan syndroom werd in 2001 
gevonden (1). Sindsdien zijn daar verschillende mutaties bijgekomen. Bij ongeveer 80% 
van patiënten waar klinisch het Noonan syndroom wordt gediagnosticeerd, wordt nu 
een mutatie gevonden in een van de bekende genen in het Noonan syndroom. 
Genotype-fenotype studies vertonen grote variabiliteit, ook binnen families. Dat wil 
zeggen dat patiënten met eenzelfde mutatie in het gen, hele verschillende symptomen 
kunnen hebben. Een belangrijk doel van dit proefschrift is om de klinische kennis en 
de herkenning van het Noonan syndroom te verbeteren. 
In dit proefschrift wordt onderzoek gedaan naar gehoorverlies en oogkenmerken in 
het Noonan syndroom en tevens hebben we een grote Noonan syndroom familie met 
een nieuwe variant van een mutatie beschreven. Met beter inzicht in de 
gehoorproblemen en oogafwijkingen waaronder slechtziendheid, kan de 
gezondheidszorg voor de Noonan syndroom patiënten worden verbeterd. Verder 
zullen genotype-fenotype correlaties helpen bij het diagnosticeren van het Noonan 
syndroom en kan de zorg en follow-up voor patienten met het Noonan syndroom 
worden geoptimaliseerd. 
Genotype, fenotype en correlaties
Tot 2001 werd het Noonan syndroom uitsluitend gediagnosticeerd door klinische 
kenmerken. In 2001 was het PTPN11 gen het eerste gen waarvan werd ontdekt dat een 
mutatie het Noonan syndroom kon veroorzaken (1). Op dit moment kan in ongeveer 
80% de klinische diagnose worden ondersteund met het aantonen van één van de 
bekende mutaties. Derhalve is het Noonan syndroom nog steeds een klinische 
diagnose, maar weten we steeds meer over de genetica. Van der Burgt beschreef in 
1994 een scoringsysteem voor de diagnose van het Noonan syndroom (2). De klinische 
diagnose wordt bij voorkeur bevestigd door het aantonen van een mutatie in de Ras-
MAPK signaalroute.
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In de afgelopen jaren zijn er verschillende studies gedaan naar de genen die 
verantwoordelijk zijn voor Noonan syndroom. Het aantonen van genetische mutaties 
voor de diagnose Noonan syndroom, wordt dan ook steeds belangrijker. Vanwege de 
verschillende genen die het Noonan syndroom en de gerelateerde syndromen 
veroorzaken, is standaard diagnostisch testen van alle genen een duur en relatief lang 
proces. Next generation sequencing (waarbij verschillende gewenste genen in één keer 
kunnen worden onderzocht), wordt voorgesteld als een meer accurate en 
kosteneffectieve genotypering. Noonan syndroom en overige syndromen binnen de 
Ras-MAPK pathway, hebben veel genetische en fenotypische heterogeniteit. Voor een 
eenvoudige en meer betrouwbare manier om te diagnosticeren, verwachten we dat 
onder andere de next generation sequencing een belangrijke rol zal spelen in de nabije 
toekomst. Genotypische karakterisering die zal leiden tot een vroege diagnose, ook bij 
patiënten met milde of atypische klinische kenmerken, zal de klinische zorg voor 
patienten met het Noonan syndroom op die manier verder kunnen verbeteren (3).
Genotype-fenotype-correlaties bij het Noonan-syndroom zijn in de literatuur een 
veelbesproken onderwerp. PTPN11 mutaties worden gevonden bij ongeveer 50% van 
de patiënten met het Noonan syndroom en tot de frequent beschreven kenmerken 
horen de korte lengte, borstkasafwijkingen, hartafwijkingen en uiterlijke kenmerken 
in het gezicht (4,5). Zeer typische gezichtskenmerken worden ook beschreven bij 
patiënten met KRAS mutaties (6) evenals cognitieve stoornissen die vaker voorkomen 
bij patiënten met KRAS mutaties (7). Frequent beschreven kenmerken bij patiënten met 
SOS1 mutaties zijn cardiale afwijkingen, gezichtskenmerken en ectodermale 
abnormaliteiten (8). In de literatuur wordt een breed scala aan klinische kenmerken 
beschreven, van zeer mild tot heel typisch in zowel patiënten  met als zonder 
aangetoonde mutatie 
In Hoofdstuk 2 presenteren we een grote Noonan familie met een nieuwe variant van 
een SOS1 mutatie. Het fenotype vertoont een breed spectrum aan kenmerken, 
variërend van slechts één enkel suggestief kenmerk tot multipele typische kenmerken 
van het Noonan syndroom. De meeste typische kenmerken werden gevonden in de 
jongste generatie van het gezin met ook binnen die jongste generatie weer verschillen. 
Onze studie bevestigt binnen één familie grote variatie in klinische kenmerken binnen 
dezelfde SOS1 mutatie. In de literatuur worden verschillende verklaringen genoemd 
voor dit soort verschillen bij dezelfde mutaties, zoals epigenetische mechanismen, 
verschillen in allel expressie en niet-coderende regio’s die betrokken zijn bij de etiologie 
(9-11). 
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   113 24-09-18   08:45
CHAPTER 8
114    
Oogafwijkingen
Oogafwijkingen worden beschreven als een zeer veel voorkomend symptoom in het 
Noonan syndroom (12,13), maar er zijn maar weinig studies die nauwkeurig en 
uitgebreid oogheelkundig onderzoek hebben gedaan. In hoofdstuk 3 beschrijven we 
het complete oogheelkundige onderzoek dat we prospectief hebben uitgevoerd bij 
25 patiënten met het Noonan syndroom. Uitwendige oogafwijkingen vormen een 
belangrijk onderdeel van de gezichtskenmerken. Andere vaak voorkomende 
afwijkingen zijn refractie afwijkingen (zoals bijziend of verziend), amblyopie (lui oog), 
strabismus (scheelzien) en abnormale stereopsis (zien van diepte). Andere specifieke 
afwijkingen omvatten prominente corneazenuwen, een posterieur embryotoxon en 
afwijkingen van de oogzenuw. Onze prospectieve observationele studie toont de 
verscheidenheid van meerdere oogafwijkingen bij het Noonan syndroom gelinkt aan 
de mutaties. We includeerden één patiënt met een BRAF mutatie en deze patiënt 
vertoonde de laagste gezichtsscherpte met oogzenuw hypoplasie. Verder vonden we 
een hoge prevalentie van ptosis (laaghangend bovenooglid), inclusief een 
uitgesproken asymmetrie tussen het rechter en linkeroog. Concluderend vonden we 
een uitgebreide variëteit aan aangeboren oogafwijkingen, die werden gekenmerkt 
door ontwikkelingsafwijkingen van de oogleden en geassocieerd zijn met andere 
oogafwijkingen in de kindertijd.
In Hoofdstuk 4 presenteren we gegevens uit een grote cohort studie. We includeerden 
oogheelkundige en genetische gegevens van 105 patiënten. Naast de incidentie van 
oogheelkundige afwijkingen en de mutaties, waren we ook geïnteresseerd in hoeverre 
de internationale richtlijnen worden gevolgd (14). In onze hypothese verwachtten we 
de oogheelkundige  bevindingen van onze prospectieve studie te bevestigen. We 
vonden een verminderde visus bij zeven patiënten; vijf van hen hadden mutaties in 
respectievelijk het RAF1, SHOC2 of KRAS gen. Externe oog afwijkingen, refractie 
afwijkingen (myopie, hypermetropie en astigmatisme), amblyopie en strabismus 
werden frequent gevonden. Andere opvallende bevindingen waren nystagmus, 
keratoconus en afwijkingen aan de oogzenuw. Het was opmerkelijk om te zien dat, 
hoewel er sterke aanbevelingen zijn om een  uitgebreid oogheelkundig onderzoek uit 
te voeren zodra de diagnose Noonan syndroom wordt gesteld, er negen patiënten 
waren die nog nooit een oogarts hadden bezocht en bij drie andere patiënten was er 
een vertraging van vele jaren voordat ze hun eerste oogheelkundige onderzoek 
ondergingen. In de richtlijnen wordt doorverwijzing naar een oogarts en orthoptist 
reeds al aanbevolen. Verdere behandeling en follow-up moeten worden uitgevoerd 
door de oogarts (14).
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Gehoorverlies en oorafwijkingen
Gehoorverlies werd voor het eerst in 1976 beschreven bij het Noonan syndroom (15) 
en wordt sindsdien in enkele studies besproken (16,17). Externe oorafwijkingen worden 
frequent beschreven in het Noonan syndroom als onderdeel van uiterlijke faciale 
kenmerken. In hoofdstuk 5 presenteren we gegevens over gehoorverlies, externe 
oorafwijkingen en genetische bevindingen bij 97 patiënten. Het gehoorverlies was 
onderverdeeld in vier categorieën: perceptieve gehoorbeschadiging, gemengd 
gehoorverlies, permanent geleidend (conductief) gehoorverlies en tijdelijk 
gehoorverlies. Negen patiënten hadden perceptief gehoorverlies en vier van hen 
hadden een ernstige aangeboren gehoorafwijking. Bij alle vier de patiënten met 
ernstige aangeboren gehoorafwijkingen werd een mutatie in het PTPN11 gen gevonden 
en ze ontvingen alle vier cochleaire implantaten met goede resultaten. In de literatuur 
zijn eerder 2 Noonan patiënten beschreven met succesvolle cochleaire implantaten 
en beiden hadden ook een mutatie in het PTPN11 gen (18). Permanent conductief 
gehoorverlies en gemengd gehoorverlies werden gevonden bij 2 patiënten. Een tijdelijk 
gehoorverlies werd gezien bij 20 patiënten als gevolg van otitis media met effusie. 
Mogelijke onderliggende (aangeboren) afwijkingen die gehoorverlies veroorzaken bij 
het Noonan syndroom zijn verschillende afwijkingen aan het binnenoor, maar ook  de 
combinatie van afwijkingen aan het binnenoor plus geleidend gehoorverlies door otitis 
media kan leiden tot een gemengd gehoorverlies. Tevens kunnen chronische en 
meervoudige otitis media infecties leiden tot een perceptief gehoorverlies. Zowel 
congenitaal gehoorverlies als verworven en progressief gehoorverlies spelen een rol 
bij het Noonan syndroom (16-18). 
Perceptief gehoorverlies wordt gevonden in het Noonan syndroom en andere 
RASopathieën, waaronder het Noonan syndroom met multipele lentigines (NS-ML). 
Counseling en zorg op maat maken het mogelijk dat de meerderheid van de patiënten 
met een RASopathie en gehoorverlies, normaal functioneren op volwassen leeftijd. 
Cochleaire implantaten kunnen daar een belangrijke rol in spelen, bij patiënten met 
ernstig bilateraal perceptief gehoorverlies. Daarom hebben we de uitkomst van vijf 
kinderen met cochleaire implantaten beschreven in hoofdstuk 6. Dit onderzoek 
beschrijft vier patiënten met het Noonan syndroom en één met het Noonan syndroom 
met multipele lentigines, allemaal met een mutatie in het PTPN11 gen. Na cochleaire 
implantatie verbeterden de audiologische resultaten, inclusief spraakherkenning, bij 
alle vijf de patiënten. Ook in de literatuur hebben alle patiënten met een ernstig 
gehoorverlies en een succesvol cochleair implantaat, een mutatie in het PTPN11 gen 
(19). Perceptief gehoorverlies is een kenmerk dat regelmatig voorkomt in het Noonan 
syndroom en andere RASopathieën, waaronder het Noonan syndroom met multipele 
201846 Dorothée v Trier_binnenwerk9,5/13,7.indd   115 24-09-18   08:45
CHAPTER 8
116    
lentigines en daarom moeten audiologische en otologische onderzoeken bij alle 
patiënten worden uitgevoerd.
Toekomst
In de nabije toekomst zullen we meer mutaties ontdekken en de genetische mutaties 
in relatie tot de kliniek steeds beter gaan begrijpen. Meer studies zullen nodig zijn om 
hier stappen in te kunnen zetten. Op het moment dat wij de pathway en de genotype-
fenotype relaties beter begrijpen, zullen er mogelijk ook nieuwe behandeling komen 
die kunnen aangrijpen op de ingewikkelde Ras-MAPK signaal pathway. Verder zijn er 
vooralsnog bescheiden aantallen beschikbaar in de literatuur en zijn het doorgaans 
relatief kleine cohort studies. Een samenwerking met het aanleggen van 1 grote 
database om alle klinische kenmerken en mutaties in te verzamelen op internationaal 
niveau zou een mooie stap zijn. Ook de ‘managment guidelines’ die internationaal zijn 
opgesteld in 2010 zijn een mooi voorbeeld van zo’n samenwerking (14). Deze richtlijnen 
zijn inmiddels ook in het Nederlands vertaald. 
Om de zorg van de Noonan patiënten verder te optimaliseren, zou allereerst de richtlijn 
gevolgd moeten worden, dus met adequaat onderzoek voor onder andere het gehoor 
en de visus. De zorg centreren in een multidisciplinair centrum dat gespecialiseerd is 
in Noonan syndroom, maakt het opvolgen van de richtlijnen makkelijker. Maar ook 
het efficiënt en goed regelen van alle begeleiding, screening en behandelingen voor 
Noonan patiënten wordt op die manier geoptimaliseerd. Daarnaast wordt participatie 
in (internationale) studies op die manier makkelijker. Er zijn al verscheidende initiatieven 
die hiermee bezig zijn. Hopelijk gaan we hier spoedig resultaten van zien!
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Veel dank aan alle Noonan syndroom families en patiënten die hebben geparticipeerd 
in dit onderzoek!
Collegae chirurgie uit het St Antonius ziekenhuis en UMC Utrecht, dank voor de leuke 
en leerzame tijd de afgelopen jaren. Mijn onderzoek was altijd een vreemde eend in 
de bijt en ik heb jullie dan ook nooit lastig hoeven vallen met presentaties op 
refereeravonden, maar ik denk wel dat vele van jullie het Noonan syndroom nu in ieder 
geval van naam kennen.
Collegae (oud-) onderzoekers chirurgie UMC Utrecht, In mijn jaar als AKO hebben jullie 
mij geadopteerd en heb ik toch nog veel onderzoek tips en tricks kunnen inwinnen. 
Door jullie voelde ik mij dat jaar voor het eerst ook een beetje onderzoeker. Dank voor 
jullie gezelligheid.
Haarlemgang toppers, thanks voor jullie support.
Lieve Aat, al vanaf 2001 beste maatjes en veel overlap in onze keuzes, tot aan een 
chirurgisch vak ambiëren. Heel heel heel graag wilde jij mijn paranimf worden en 
heel heel leuk vond ik het dan ook toen ik je hiervoor kon vragen. Ik weet zeker dat 
als ik het kan afronden, jij het ook kan! Dank voor alle gezelligheid de afgelopen jaren 
en dank ook voor je enthousiasme als paranimf. Op naar jouw promotie en 
opleidingsplek!
Lieve Ing, als iemand de afgelopen jaren trouw informeerde naar de voortgang van 
mij onderzoek, dan was jij het wel! Niet altijd mijn favoriete gespreksonderwerp, maar 
wel heel lief! Gelukkig is het nu klaar. Thanks voor je interesse en alle borrels de 
afgelopen jaren.
Beste Bram, Dit boekje ziet er echt geweldig uit met dank aan jou! Je hebt voor mij een 
geweldig ontwerp gemaakt, ik had mij geen mooiere kaft kunnen wensen. Met minimale 
uitleg over de inhoud, heb jij deze omslag weten te maken. Heel veel dank!
Lieve familie en vrienden, velen van jullie hebben meegeleefd de afgelopen jaren met 
mijn onderzoek. Dank daarvoor!  Ik hoop jullie op 20 en 23 november op een drankje 
te kunnen trakteren en bedanken. 
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Lieve ouders, Volgens mij hebben jullie je regelmatig afgevraagd of ik dit boekje tot 
een goed einde ging brengen. Ik lijk niet altijd op vaders. Heel veel dank voor al jullie 
meedenken en altijd weer verwennerij in Bloemendaal en Roche. Vanaf nu nooit meer 
achter dat bureau in Roche. Maar vooral dank voor jullie opvoeding en liefde, die mij 
hier hebben gebracht. Jullie zijn geweldig!
Lieve Puck, lieve zuster en paranimf, Wat ben ik af en toe jaloers geweest op jouw 
discipline, dan had ik dit boekje waarschijnlijk allang afgerond. Jij toont altijd interesse, 
vragen hoe het met het onderzoek staat en pogingen doen mij te motiveren, ook al 
vond ik de biertjes en etentjes veel interessanter! Ik ben super trots op mijn kleine 
zusje en vind het heel leuk dat je mijn paranimf bent!
Lieve Teun, Yes, toch niet mijn promotie misgelopen! Niet in juli, en gelukkig nu ook 
net op tijd terug! Mijn promotietraject toont wel wat overeenkomsten met jouw studie. 
Net als voor mijn lange promotietraject is ook voor jouw studie gelukkig het einde in 
zicht! Ik ben heel blij met jou, Puck (en Robin natuurlijk). Jouw vrolijkheid en humor 
maken elk moment weer gezellig. Op naar de volgende fuif!
Lieve Oma, Volgens mij was jij het die voor het eerst het balletje opgooide om eens 
met Jos te gaan praten en daarmee bleek de basis voor mijn promotieonderzoek 
gelegd. Een tijdje terug liet je mij het promotieboek van opa zien, wat een ingewikkelde 
materie. Ik hoop dat mijn boekje naast het ingewikkelde promotiewerk van opa in de 
kast mag!
Daantje, ik ben super blij met jou, kus!
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